

12.1 General BGEM Test Card Specifications

12.1.1 Indications for Use – epoc[®] Blood Analysis System

RxOnly

The **epoc[®] Blood Analysis System** is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

The **Blood Gas Electrolyte and Metabolite (BGEM) Test Card** panel configuration includes sensors that quantitate pH, $p\text{CO}_2$, $p\text{O}_2$, Sodium, Potassium, Ionized Calcium, Chloride, Total Carbon Dioxide, Glucose, Lactate, Blood Urea Nitrogen, Creatinine, and Hematocrit.

pH, $p\text{CO}_2$, $p\text{O}_2$ (blood gases) measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of life-threatening acid-base disturbances.

Sodium and **Potassium** measurements from the epoc Blood Analysis System are used in diagnosis and treatment of diseases involving electrolyte imbalance.

Ionized Calcium measurements from the epoc Blood Analysis System are used in diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany.

Chloride measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of electrolyte and metabolic disorders.

Total Carbon Dioxide measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of disorders associated with changes in body acid-base balance.

Glucose measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of carbohydrate metabolism disorders, including diabetes mellitus and idiopathic hypoglycemia, and of pancreatic islet cell tumors.

Lactate measurements from the epoc Blood Analysis System are used to evaluate the acid-base status and are used in the diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).

Blood Urea Nitrogen measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of certain renal and metabolic diseases.

Creatinine measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of certain renal diseases and in monitoring renal dialysis.

Hematocrit measurements from the epoc Blood Analysis System are used to distinguish normal from abnormal states of blood volume, such as anemia and erythrocytosis.

12.2 Test Card Configuration and Use

The epoc Blood Gas Electrolyte and Metabolytes (BGEM) Test Cards include the following measured and calculated Test Results.

epoc BGEM CT-1006-00-00/SMN 10736382 pH $p\text{CO}_2$ $p\text{O}_2$ Sodium Na+ Potassium K+ Ionized Calcium Ca++ Chloride Cl- Glucose Glu Lactate Lac Creatinine Crea Hematocrit Hct *Bicarbonate CHCO_3^- *Calculated Total Carbon Dioxide cTCO_2 *Base excess BE *Oxygen Saturation cSO_2 *Alveolar Oxygen A *Arterial Alveolar Oxygen Tension Gradient A-a *Arterial Alveolar Oxygen Tension Ratio a/A *Anion Gap AGap *Anion Gap K+ AGapK *Estimated Glomerular Filtration Rate: ○ GFRmdr (IDMS-traceable MDRD) ○ GFRmdr-a (IDMS-traceable MDRD, if African-American) ○ GFRckd (CKD-EPI equation) ○ GFRckd-a (CKD-EPI equation, if African-American) ○ GFRckd21 (CKD-EPI equation, race-independent) ○ GFRswz (Bedside Schwartz equation) *Hemoglobin cHgb	epoc BGEM SMN 10736515 pH $p\text{CO}_2$ $p\text{O}_2$ Sodium Na+ Potassium K+ Ionized Calcium Ca++ Chloride Cl- Total Carbon Dioxide TCO_2 Glucose Glu Lactate Lac Blood Urea Nitrogen (BUN), Urea Creatinine Crea Hematocrit Hct *Bicarbonate CHCO_3^- *Calculated Total Carbon Dioxide $\text{cTCO}_2^\dagger$ *Base excess BE *Oxygen saturation cSO_2 *Alveolar Oxygen A *Arterial Alveolar Oxygen Tension Gradient A-a *Arterial Alveolar Oxygen Tension Ratio a/A *Anion Gap AGap, AGapK *Estimated Glomerular Filtration Rate: ○ GFRmdr (IDMS-traceable MDRD) ○ GFRmdr-a (IDMS-traceable MDRD, if African-American) ○ GFRckd (CKD-EPI equation) ○ GFRckd-a (CKD-EPI equation, if African-American) ○ GFRckd21 (CKD-EPI equation, race-independent) ○ GFRswz (Bedside Schwartz equation) *BUN/Crea ratio, Urea/Crea ratio *Hemoglobin cHgb
---	---

* *Calculated values*

† *Calculated TCO_2 is only available when measured TCO_2 is not reported.*

Note: *Some tests are not available in all markets.*

The SMN 10736515 epoc BGEM Test Card is identical to its predecessor, the CT-1006-00-00/ SMN 10736382 BGEM Test Card, except for that the SMN 10736515 epoc BGEM Test Card features BUN/Urea sensors printed into previously empty sensor wells, as well as the measured TCO_2 test. Therefore, all other card components and common biosensors are identical on both products.

12.2.1 Storage Stability



Test Cards must be stored in their Card Pouch at Room Temperature, 15°C to 30°C (59°F to 86°F), at all times. Never fridge store or allow Test Cards to freeze.

12.2.2 Additional Information

Refer to Section 3 “epoc System Operation” in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 “Quality Assurance” in this manual for quality control requirements.

12.2.3 Test Timing

The initiation of a test starts with establishing a communications link between the Host and Reader. Test Card is removed from Card Pouch. Card should be inserted immediately into Reader. During 150-175 second (approximate) calibration period User acquires blood sample for test. After calibration is complete, Reader Indicator and epoc Host inform User that Card is ready to receive blood sample. Card is now ready for sample introduction, and sample can be introduced at any time thereafter for up to 450 seconds (7.5 minutes), after which the sample introduction period times-out, and can no longer accept sample. Thirty nine (39) seconds after sample introduction, testing is complete (47 seconds for QA test). Results are then calculated, saved and displayed. Test card can be removed from the Reader and discarded in biohazard waste.

12.2.4 Sample Type

Fresh whole blood from arterial, venous, or capillary sources, is introduced to the card using a Syringe or epoc Care-Fill™ Blood Collection Tube. See “Sample Collection Details” below for the time periods when the blood is considered fresh and thus suitable for testing.

12.2.5 Sample Volume

At least 92 microliters.

Note: The epoc Care-Fill Capillary Tube capacity is 90 microliters plus the volume of air pushed behind the sample when the plunger is fully depressed, which brings it to over 92 microliters.

12.2.6 Sample Collection

The epoc System is designed for point-of-care blood analysis. Test samples immediately after drawing a sample to obtain results that represent patient status with greatest accuracy.

Please note that all epoc System tests are categorized as having moderate complexity (non-waived status) under CLIA.



Always use ISO 80369-7 compliant Syringe for sample introduction.



The epoc System is intended to be used with fresh whole blood samples only. Do not use clotted samples.



Always wear protective gloves when handling blood samples.



The specimen used to fill a Test Card must be collected and handled properly to ensure that the results represent Patient's current status.



Blood samples must be collected according to the facility's policies and procedures. Always follow the specific instructions provided by other medical manufacturers when considering information in this section.



When anticoagulants are needed, use exclusively heparin for the anticoagulant.

See table below for additional options for specific tests and sample collection methods.

Test	Sample Collection Details <i>(see also References at the end of the present subsection)</i>		
	Syringes • 1 or 3 mL plastic • Without anticoagulant must be run within 3-5 min • With Li or Na heparin • With balanced heparin	Evacuated Tubes • With Li or Na heparin • Without anticoagulant must be run immediately <i>Note that clot activators may be present in some collection devices</i>	Capillary Tubes • epoc Care-Fill Capillary Tubes only
pO₂	• Non-iced syringes^{1,2} • Test in less than 30 min^{1,2}	• Not recommended¹	• Test in less than 5 min recommended
pH⁺ / pCO₂	• Test in less than 30 min^{1,2}	• Test in less than 30 min^{1,2}	• Test in less than 5 min recommended
TCO₂	• Test in less than 30 min to avoid possible air contamination^{22, 23, 24} and/or artifacts of metabolic activity^{11,12}	• Do not underfill^{***} • Test in less than 30 min to avoid artifacts of metabolic activity^{11,12}	• Test in less than 5 min recommended
Ca++ ****	• With Li or Na heparin only if <10 IU/mL³ • With balanced heparin only if <70 IU/mL³ • Test in less than 30 min to avoid artifacts of metabolic activity^{1,2,3}	• With Li or Na heparin only if <10 IU/mL³ • Tube should be filled to its nominal volume³ • Test in less than 30 min to avoid artifacts of metabolic activity^{1,2,3}	• Care-Fill capillary tubes contain 65 IU/mL of calcium balanced lithium heparin • Test in less than 5 min recommended
Glu	• Test in less than 30 min to avoid effects of glycolysis^{11,12}	• With Li or Na heparin only (do not use NaF) • Test in less than 30 min to avoid effects of glycolysis^{11,12}	• Test in less than 5 min recommended
Lac	• Test in less than 5 min to avoid effects of glycolysis¹³	• With Li or Na heparin only (do not use NaF) • Test in less than 5 min to avoid effects of glycolysis¹³	• Test in less than 5 min recommended

Test	Sample Collection Details (see also References at the end of the present subsection)		
	Syringes • 1 or 3 mL plastic • Without anticoagulant must be run within 3-5 min • With Li or Na heparin • With balanced heparin	Evacuated Tubes • With Li or Na heparin • Without anticoagulant must be run immediately <i>Note that clot activators may be present in some collection devices</i>	Capillary Tubes • epoc Care-Fill Capillary Tubes only
Hct	• Immediate testing is recommended in order to avoid RBC settling (<i>Note: Re-suspension of RBC requires an air bubble of significant volume⁴</i>)	• With Li or Na heparin only (do not use EDTA) • Test in less than 1 h to avoid effects of glycolysis and electrolyte shifts¹⁴	• Immediate testing is recommended in order to avoid RBC settling
All other tests	• Test in less than 1 h to avoid effects of glycolysis and electrolyte shifts¹⁴	• With Li or Na heparin** • Test in less than 1 h to avoid effects of glycolysis and electrolyte shifts¹⁴	• Test in less than 5 min recommended

* Non-iced samples recommended. Iced samples may cause increased pH internal quality control failures.

** Use of evacuated collection tubes containing Na heparin may cause a positive error on the sodium results.¹⁵ See also Section 12.6.7 D.

*** Underfilling blood collection tubes may cause decrease of TCO₂ results. Always follow manufacturer recommendations for sample collection devices. See also Section 12.10.7 D.

**** When using evacuated tubes with heparin, the tubes should be filled to their nominal volume. This will keep binding of calcium ions by heparin at a minimum and consistent level.³

Note: The effect of heparin salts on calcium binding is such that each 5 IU/mL of heparin lowers ionized calcium concentrations by about 0.01 mmol/L.³ Standard evacuated blood collection tubes have a heparin concentration of ≤17 IU/mL.

12.2.7 Interpretation of Results

If Patient Test Results are inconsistent with clinical assessment, a fresh Patient sample should be collected and tested on another card.

Look further in this section for information on factors affecting results of various sensors. Certain substances, such as drugs, may affect the Test Results⁵⁻⁷.

12.2.8 Measurement ranges (some values may be rounded)

Note: The tables below provide the data for reference ranges as published in literature (see references for details). Institutions should confirm their own reference range values.

Measured Parameters			
Test	Units of Measure	Measurement Range	Reference Range ^{8-10,22}
pH	pH units	6.5 – 8.0	7.35 – 7.45 arterial
			7.32 – 7.43 venous
pCO ₂	mmHg	5 – 250	35 – 48 arterial
			41 – 51 venous
	kPa	0.7 – 33.3	4.7 – 6.4 arterial
			5.4 – 6.8 venous
pO ₂	mmHg	5 – 750	83 – 108 arterial**
	kPa	0.7 – 100	11.1 – 14.4 arterial**
Na ⁺	mmol/L	85 – 180	138 – 146
	mEq/L		
K ⁺	mmol/L	1.5 – 12.0	3.5 – 4.5
	mEq/L		
Ca ⁺⁺	mmol/L	0.25 – 4.00	1.15 – 1.33
	mg/dL	1.0 – 16.0	4.6 – 5.3
	mEq/L	0.5 – 8.0	2.3 – 2.7
Cl ⁻	mmol/L	65 – 140	98 – 107
	mEq/L		
TCO ₂	mmol/L	5 – 50	22 – 29 arterial
			23 – 30 venous
	mEq/L	5 – 50	22 – 29 arterial
			23 – 30 venous
Glu	mmol/L	1.1 – 38.5	4.1 – 5.5
	mg/dL	20 – 700	74 – 100
	g/L	0.20 – 7.00	0.74 – 1.00
Lac	mmol/L	0.30 – 20.00	0.36 – 0.75 arterial
			0.56 – 1.39 venous
	mg/dL	2.7 – 180.2	3.2 – 6.8 arterial
			5.0 – 12.5 venous
	g/L	0.03 – 1.80	0.03 – 0.07 arterial
			0.05 – 0.12 venous
BUN	mg/dL	3 – 120	8-26
Urea	mmol/L	1.1 – 42.8	2.9 – 9.3
	mg/dL	7 – 257	17 – 56
	g/L	0.07 – 2.57	0.17 – 0.56
Crea	mg/dL	0.30 – 15.00	0.51 – 1.19
	μmol/L	27 – 1326	45 – 105
Hct	% PCV	10 – 75	38 – 51
	L/L	0.10 – 0.75	0.38 – 0.51

* Some units for Glucose may not be available in all regions.

** As per CLSI C46-A2¹, arterial blood samples are preferred for blood gas analysis. Therefore, reference ranges for arterial blood gases may not be directly applied to venous and capillary blood gases. Note that there are conflicting reports¹⁶⁻²¹ regarding the validity of pO₂ analysis performed on arterialized capillary blood samples, compared to arterial pO₂. Variability in both capillary collection process and in capillary blood itself may affect test results for pH, pO₂, pCO₂, and calculated sO₂ of capillary samples.

Calculated Parameters			
Acronym	Units of Measure	Measurement Range	Reference Range ^{8-10,22}
cHCO₃⁻	mmol/L	1 – 85	21 – 28 arterial
			22 – 29 venous
	mEq/L	1 – 85	21 – 28 arterial
			22 – 29 venous
cTCO₂	mmol/L	5 – 50	22 – 29 arterial
			23 – 30 venous
	mEq/L	5 – 50	22 – 29 arterial
			23 – 30 venous
BE(ecf)	mmol/L	-30 – +30	-2 – +3
	mEq/L		
BE(b)	mmol/L	-30 – +30	-2 – +3
	mEq/L		
cSO₂	%	0 – 100	94 – 98 arterial
A	mmHg	5-800	†
	kPa	0.67-106.64	†
A-a	mmHg	1-800	†
	kPa	0.13-106.64	†
a/A	%	0-100	†
	fraction	0-1	†
AGap	mmol/L	-14 – +95	7 – 16
	mEq/L		
AGapK	mmol/L	-10 – +99	10 – 20
	mEq/L		
GFRmdr, GFRmdr-a	mL/min/1.73m ²	2 – 60 or >60*	†
GFRckd, GFRckd-a, GFRckd21	mL/min/1.73m ²	1 – 225	†
GFRswz	mL/min/1.73m ²	1 – 275	†
BUN/Crea	mg/mg	0.2 – 400.0	12.0 – 20.0
Urea/Crea	mmol/mmol	0.8 – 1615.4	48.5 – 80.8
	mg/mg	0.4 – 856.8	25.7 – 42.9
cHgb	g/dL	3.3 – 25	12 – 17
	mmol/L	2.0 – 15.5	7.4 – 10.6
	g/L	33 – 250	120 – 170

* Numeric values will be reported for values between 2-60 mL/min/1.73 m². Values >60 will be reported as > 60 mL/min/1.73 m². This range is based on the specific National Kidney Disease Education Program (NKDEP) recommendation for reporting GFRmdr values. These ranges are based on the specific National Kidney Disease Education Program (NKDEP) recommendation for reporting GFRmdr values. Please refer to the following web link: <http://nkdep.nih.gov/lab-evaluation/gfr/reporting.shtml>. GFRmdr > 60 does not exclude the possibility of mild renal disease. Further laboratory testing may be necessary to distinguish normal renal function from mild renal disease.

† Widely accepted reference ranges are not well established. Institutions should establish and set their own reference range values.

12.2.9 References

1. CLSI C46-A2, Vol. 29, No. 8, Blood gas and pH analysis and related measurements- Approved Guideline, second edition, Wayne, Pennsylvania, USA, 2009.
2. CLSI H11-A4, Vol. 24, No. 28, Procedures for the collection of arterial blood specimens- Approved Standard, Wayne, Pennsylvania, USA, 2004.
3. CLSI C31-A2, Vol. 21, No. 10, Ionized Calcium Determinations: recollection variables, specimen, choice, collection and handling, approved guideline, second edition, Wayne, Pennsylvania, USA, 2001.
4. CLSI H07-A3, Vol. 20, No. 18, Procedures for determining packed cell volume by micro-hematocrit method- Approved Standard, Wayne, Pennsylvania, USA, 2000.
5. T.P. Moyer, L.M. Shaw, Chapters 33 of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
6. D.S. Young, Effects of Drugs on Clinical Laboratory Tests, third edition, AACC Press, Washington DC, 1990.
7. N.W. Tietz, Clinical Guide to Laboratory Tests, 3rd Edition, W.B. Saunders Company, 1995.
8. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
9. B.E. Statland, Clinical Decision Levels for Lab Tests, Medical Economic Books, Oradell, NJ, 1987.
10. F. Ceriotti, et al, IFCC Committee on Reference Intervals and decision limits (C-RIDL), "Reference Intervals for Serum Creatinine Concentrations: Assessment of Available Data for Global Application", Clin Chem, 54:3, p559-566, 2008.
11. D.B. Sacks, Chapter 25 (p. 837) of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
12. Chapter 141, Blood Glucose of J. Michael McMillin, Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations, third edition. Boston: Butterworths; 1990.
13. D.B. Sacks, Chapter 22 (p. 929) of Tietz Textbook of Clinical Chemistry, second edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, Philadelphia, 1994.
14. M.G. Scott, V.A. LeGrys, J.S. Klutts, Chapter 27 (p.985) of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, D.E. Bruns eds, Elsevier Saunders, St. Louis, 2006.
15. D. Young, E. Bermes, Jr, Chapter 2 of Tietz Textbook of Clinical Chemistry, third edition, C.A. Burtis and E.R. Ashwood, eds., W.B. Saunders Company, Philadelphia, 1999.
16. Courtney S.E. et al., Capillary Blood Gases in the Neonate, Am. J. of Diseases of Children, vol 144 (2), p. 168-172, 1990.
17. Eaton T. et al., The clinical utility of arterialized earlobe capillary blood in the assessment of patients for long-term oxygen therapy, Respiratory Medicine, vol. 95(8), p.655-660, 2001.

18. Fajac I. et al., Blood gas measurement during exercise: a comparative study between arterialized earlobe sampling and direct arterial puncture in adults, *The European Respiratory Journal*, vol. 11(3), p. 712-715, 1998.
19. Sauty A. et al., Differences in pO_2 and pCO_2 between arterial and arterialized earlobe samples, *European Respir. J.*, vol. 9, p. 186-189, 1996.
20. Zavorsky G.S. et al., Arterial versus capillary blood gases: A meta-analysis, *Respiratory Physiology & Neurobiology*, vol. 155(3), p. 268-279, 2007.
21. *The Blood Gas Handbook*, Radiometer Medical ApS, Denmark, 2011.
22. Pruden E.L., Siggaard-Andersen O., and Tietz N.W., Chapter 30 (Blood Gases and pH), of *Tietz Textbook of Clinical Chemistry*, Second Edition, ed. C.A. Burtis and E.R. Ashwood. W.B. Saunders Company, Philadelphia, 1994.
23. Gambino et al., "The measurement of CO_2 content with the autoanalyzer", *Am.J.Clin Path*, 45, p. 406, 1966.
24. Ungerer et al., "Discordance between measured and calculated total carbon dioxide", *Clin.Chem.*, 36 (12), p. 2093-2096, 1990.

12.3 pH

pH is measured by potentiometry using a pH selective membrane electrode. The concentration of hydrogen ions is obtained from the measured potential using the Nernst equation.

12.3.1 Indications for Use

The pH test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Measurement of pH, $p\text{CO}_2$, $p\text{O}_2$ (blood gases) is used in the diagnosis and treatment of life-threatening acid-base disturbances.

12.3.2 Contents

Each Test Card incorporating a pH test contains a hydrogen ion sensing electrode with a hydrogen ion selective membrane, a reference electrode and a calibrator fluid containing a known concentration of pH buffer salts.

12.3.3 Traceability

Values of pH assigned to controls and calibrator fluids are traceable to NIST standards.

12.3.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.3.5 Additional Information

Refer to Section 3 "epoc System Operation" in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 "Quality Assurance" in this manual for quality control requirements.

12.3.6 Measurement Range

	Measurement Range	Reference Range ¹	
		Arterial	Venous
pH	6.5 – 8.0	7.35 – 7.45	7.32 – 7.43

12.3.7 Temperature Correction

pH is a temperature dependent quantity, measured at 37°C on the epoc System. The pH value can be corrected to the Patient's temperature. Patient temperature is entered on the Test Information Page of the Reader Tab on the epoc Host (see Section 3 "epoc System Operation" in this manual).

The pH at the Patient's temperature (T, °C) is calculated as follows²:

$$\text{pH}(T) = \text{pH} - 0.0147(T - 37) + 0.0065(7.4 - \text{pH})(T - 37)$$

12.3.8 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2³ for method comparison studies, CLSI EP07-A2⁴ for interference studies and CLSI EP05-A2¹⁰ for precision studies.

A. Precision Data

In the precision data tables below, SD_{WR} denotes within run standard deviation and SD_T denotes total standard deviation.

In-house Precision 1: commercial aqueous blood gas and electrolyte controls run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 16 replicate measurements per lot per each control fluid level.

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_T	%CV
Level 1	pH units	6.992	0.007	0.10	0.010	0.15
Level 3	pH units	7.673	0.007	0.09	0.011	0.14

In-house Precision 2: commercial aqueous blood gas and electrolyte controls run in a 20 day precision study¹⁰ with 2 measurements each day per each control level. 4 manufactured lots, 6 different epoc Readers

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_T	%CV
Level 1	pH units	6.986	0.006	0.09	0.008	0.11
Level 3	pH units	7.676	0.005	0.07	0.006	0.08

In-house Precision 3: whole blood samples run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 12 replicates per each blood sample per lot.

Whole Blood Samples	Units	Mean	Mean SD_{WR}	%CV
Blood level 1	pH units	7.200	0.007	0.09
Blood level 2	pH units	7.700	0.009	0.12

Clinical Site Precision 1: 10 replicates of commercial aqueous blood gas controls run by operators of the epoc system at 3 different point-of-care sites. Each precision study employed from 2 to 4 different epoc Readers.

High pH level commercial aqueous blood gas control

	Units	Mean	SD_{WR}	%CV
Operator 1	pH units	7.679	0.004	0.05
Operator 2	pH units	7.672	0.005	0.07
Operator 3	pH units	7.685	0.009	0.12

Low pH level commercial aqueous blood gas control

	Units	Mean	SD _{WR}	%CV
Operator 4	pH units	7.101	0.005	0.07
Operator 5	pH units	7.094	0.006	0.08
Operator 6	pH units	7.088	0.013	0.18
Operator 7	pH units	7.079	0.006	0.08

Clinical Site Precision 2: 10 replicates of different whole blood Patient samples run by different operators of the epoc system at different point-of-care sites. Each precision study employed 5 different epoc Readers.

		Units	Mean	SD _{WR}	%CV
Site 1	Operator 1	pH units	7.365	0.006	0.08
	Operator 2	pH units	7.368	0.005	0.07
Site 2	Operator 3	pH units	7.322	0.005	0.07
	Operator 4	pH units	7.335	0.006	0.08
	Operator 5	pH units	7.303	0.009	0.12
Site 3	Operator 6	pH units	7.266	0.006	0.08
	Operator 7	pH units	7.381	0.004	0.05

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

This study was performed in-house on multiple whole blood samples with pH values spanning the reportable range. Linearity is reported versus an in-house standard pH electrode method with traceability to NIST standards.

	Test Range	Units	Slope	Intercept	R
pH	6.483 – 8.085	pH units	1.003	-0.030	0.999

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2³. In the method comparison statistics table, N is the number of Patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Clinical Site Method Comparison 1: In one hospital study, the epoc System was compared with the i-STAT 300⁶ in the lab (two test occasions), and then at three point-of-care sites.

Method Comparison Summary Statistics: whole blood

X: i-STAT 300 test

Y: epoc test

pH	Lab 1	Lab 2	POC 1	POC 2	POC 3	All	All*
N	34	24	35	27	22	142	149
Sxx	0.016	0.012	0.010	0.010	0.015	0.013	0.014
Syy	0.005	0.006	0.006	0.006	0.008	0.006	0.007
Intercept	0.152	0.006	0.448	-0.772	-0.367	0.029	0.251
Slope	0.978	0.999	0.938	1.104	1.050	0.995	0.966
Syx	0.019	0.021	0.013	0.015	0.024	0.018	0.020
Xmin	6.991	7.085	7.243	7.223	7.174	6.991	6.770
Xmax	7.592	7.557	7.507	7.522	7.557	7.592	7.982
R	0.993	0.985	0.961	0.981	0.985	0.987	0.991
Mean Bias (pH units)							-0.007

*This data set includes Patient samples spiked with NaOH for extended data range.

Clinical Site Method Comparison 2: In another hospital study, the epoc System was compared with the Radiometer ABL 735⁷ in the lab.

Method Comparison Summary Statistics: whole blood

X: Radiometer ABL 735

Y: epoc test

pH	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (pH units)
Lab	77	0.011	0.010	0.366	0.952	0.017	7.175	7.542	0.975	0.010

D. Limitations and Interferences

Exposure of the sample to air will affect pH, $p\text{CO}_2$, $p\text{O}_2$, TCO_2 and ionized calcium results due to the sample equilibration with the gas levels in the air, with pH and TCO_2 affected by the $p\text{CO}_2$ change⁹ and ionized calcium affected by the pH change⁸. Air contains less than 1 mmHg $p\text{CO}_2$ and about 150-180 mmHg $p\text{O}_2$. Do not introduce air bubbles into a collection device. If present, air bubbles should be removed immediately after collection.

Whole blood specimens should not be over-diluted with liquid anti-coagulants or other solutions used in therapies as this may alter results. Refer to 12.2.6 Sample Collection.

Interference testing⁴ was performed in-house on the epoc pH sensor. In each of these tests a whole blood specimen was aliquoted into two samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The pH bias between the mean of six replicates on both the control sample and the test sample with added interferent was calculated.

Clinically significant interfering substances are itemized below:

- Samples contaminated with benzalkonium salts used as coatings for in-dwelling lines may cause lower pH results². For proper line-flushing procedures refer to CLSI H11-A4⁵.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 447 mg/dL ethanol, 1 mmol/L sodium pentothal, 4.3 mmol/L acetyl salicylate, 0.4 mmol/L ascorbate, 4.3 mmol/L salicylate, 1 mmol/L iodide, 2.2 mmol/L ibuprofen, 1.66 mmol/L acetaminophen, 2 mmol/L ammonium, 4 mmol/L lithium, 35 mmol/L bromide, 2.64 mmol/L propofol, 0.7 mmol/L cefotaxime, 0.16 mmol/L ampicillin, 1 mmol/L sodium perchlorate, 4.8 µM ZofranTM, 2.5 mM N-acetylcysteine, 719 µmol/L (19.2 mg/dL) leflunomide, 1002 µmol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: 20 mmol/L NaCl, 8 mmol/L KCl, 3 mmol/L CaCl₂, 10 to 120 mmHg pCO₂, pH 6.9 to 7.7, +20 mmol/L bicarbonate, 10 mmol/L lactate, +20% PCV Hct, 3% to 11% total protein, 0.8g/dL lipids, 9.1 mmol/L cholesterol, 20 mmol/L β-hydroxybutyrate, 2mmol/L (24mg/dL) L-cysteine, 0.26 mmol/L bilirubin, +2 mmol/L phosphate.

E. References

1. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
2. CLSI. Blood Gas and pH Analysis and Related Measurements; Approved Guideline, CLSI C46-A2, Vol. 29, No. 8, Blood gas and pH analysis and related measurements- Approved Guideline, second edition, Wayne, Pennsylvania, USA, 2009.
3. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
4. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
5. CLSI. Procedures for the Collection of Arterial Blood Specimens; Approved Standard, CLSI document H11-A4 (ISBN 1-56238-545-3), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
6. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
7. Radiometer ABL 735, Radiometer Medical ApS, Åkandavej 21, DK-2700 Brønshøj, Denmark, "Radiometer" and "ABL" are registered trademarks of Radiometer Medical ApS.
8. D.B. Endres and R.K. Rude, Chapter 49 (p. 1901) of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
9. M.G. Scott, V.A. LeGrys and J.S. Klutts, Chapter 27 of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
10. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.

12.4 $p\text{CO}_2$

$p\text{CO}_2$ is measured by potentiometry using a membrane covered pH sensing electrode^{9,10}. The electrode voltage is proportional to the dissolved carbon dioxide concentration through the Nernst equation.

12.4.1 Indications for Use

The $p\text{CO}_2$ test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Measurement of pH, $p\text{CO}_2$, $p\text{O}_2$ (blood gases) is used in the diagnosis and treatment of life-threatening acid-base disturbances.

12.4.2 Contents

Each Test Card incorporating a $p\text{CO}_2$ test contains a pH sensing electrode overlaid with a bicarbonate containing membrane, a carbon dioxide permeable membrane, a reference electrode and a calibrator fluid containing a known concentration of dissolved carbon dioxide.

12.4.3 Traceability

Dissolved carbon dioxide concentration values assigned to controls and calibrator fluids are traceable to NIST standards via commercially available certified gas standards.

12.4.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.4.5 Additional Information

Refer to Section 3 "epoc System Operation" in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 "Quality Assurance" in this manual for quality control requirements.

12.4.6 Measurement Range

	Measurement Range	Reference Range ²	
		Arterial	Venous
$p\text{CO}_2$	5 – 250 mmHg	35 – 48 mmHg	41 – 51 mmHg
	0.7 – 33.3 kPa	4.7 – 6.4 kPa	5.4 – 6.8 kPa

12.4.7 Temperature Correction

$p\text{CO}_2$ is a temperature dependent quantity, measured at 37°C on the epoc System. The $p\text{CO}_2$ value can be corrected to the Patient's temperature. Patient temperature is entered on the Test Information Page of the Reader Tab on the epoc Host (see Section 3 "epoc System Operation" in this manual).

The $p\text{CO}_2$ at the Patient's temperature (T, °C) is calculated as follows¹

$$p\text{CO}_2(T) = p\text{CO}_2 \times 10^{0.019(T - 37)}$$

12.4.8 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2⁴ for method comparison studies, CLSI EP07-A2⁷ for interference studies and CLSI EP05-A2¹¹ for precision studies.

A. Precision Data

In the precision data tables below, SD_{WR} denotes within run standard deviation and SD_{T} denotes total standard deviation.

In-house Precision 1: commercial aqueous blood gas and electrolyte controls run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 16 replicate measurements per lot per each control fluid level.

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_{T}	%CV
Level 1	mmHg	86.2	1.9	2.2	2.4	2.8
Level 3	mmHg	24.1	0.5	2.1	0.7	3.0

In-house Precision 2: commercial aqueous blood gas and electrolyte controls run in a 20 day precision study¹¹ with 2 measurements each day per each control level. 4 manufactured lots, 6 different epoc Readers

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_{T}	%CV
Level 1	mmHg	80.6	1.9	2.4	2.4	2.9
Level 3	mmHg	22.5	0.4	1.6	0.6	2.5

In-house Precision 3: whole blood samples run on 20 sequential manufactured lots using at least eight (8) different epoc Readers, with 12 replicates per each blood sample per lot.

Whole Blood Samples	Units	Mean	Mean SD_{WR}	%CV
Blood level 1	mmHg	65.0	1.5	2.3
Blood level 2	mmHg	90.0	2.9	3.2

Clinical Site Precision 1: 10 replicates of commercial aqueous blood gas controls run by operators of the epoc system at three (3) different point-of-care sites. Each precision study employed from two (2) to four (4) different epoc Readers.

Low $p\text{CO}_2$ level commercial aqueous blood gas control

	Units	Mean	SD _{WR}	%CV
Operator 1	mmHg	21.2	0.4	1.9
Operator 2	mmHg	21.2	0.5	2.3
Operator 3	mmHg	20.5	1.1	5.2

High $p\text{CO}_2$ level commercial aqueous blood gas control

	Units	Mean	SD _{WR}	%CV
Operator 4	mmHg	69.0	1.2	1.7
Operator 5	mmHg	70.2	1.2	1.7
Operator 6	mmHg	68.2	1.3	1.8
Operator 7	mmHg	67.2	1.3	1.9

Clinical Site Precision 2: 10 replicates of different whole blood Patient samples run by different operators of the epoc system at different point-of-care sites. Each precision study employed 5 different epoc Readers.

		Units	Mean	SD _{WR}	%CV
Site 1	Operator 1	mmHg	52.3	2.0	3.8
	Operator 2	mmHg	49.9	0.9	1.9
Site 2	Operator 3	mmHg	56.9	0.9	1.5
	Operator 4	mmHg	55.4	1.4	2.5
	Operator 5	mmHg	58.9	1.1	1.9
Site 3	Operator 6	mmHg	61.7	1.8	2.9
	Operator 7	mmHg	41.5	0.9	2.1

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

This study was performed in-house on multiple whole blood samples with $p\text{CO}_2$ values spanning the reportable range. Linearity is reported versus an in-house standard blood gas method with traceability to NIST standards.

	Test Range	Units	Slope	Intercept	R
$p\text{CO}_2$	0.0 – 254.6	mmHg	1.039	-0.538	0.998

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2⁴. In the method comparison statistics table, N is the number of Patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Clinical Site Method Comparison 1: In one hospital study, the epoc System was compared with the i-STAT 300⁵ in the lab (two test occasions), and then at three (3) point-of-care sites.

Method Comparison Summary Statistics: whole blood

X: i-STAT 300 test

Y: epoc test

pCO₂	Lab 1	Lab 2	POC 1	POC 2	POC 3	All
N	34	24	35	28	22	143
Sxx	1.4	2.1	0.6	1.5	1.7	1.5
Syy	1.3	1.3	0.6	1.1	1.2	1.1
Intercept	-2.0	-1.2	-6.1	5.0	1.0	-0.9
Slope	1.048	1.055	1.167	0.911	0.983	1.041
Syx	3.1	2.3	1.6	2.3	2.4	2.4
Xmin	19.7	26.7	35.6	29.1	23.6	19.7
Xmax	112.2	92.5	54.4	55.6	63.0	112.2
R	0.993	0.991	0.967	0.949	0.978	0.990
Mean Bias (mmHg)						0.8

Clinical Site Method Comparison 2: In another hospital study, the epoc System was compared with the Radiometer ABL 735⁶ in the lab.

Method Comparison Summary Statistics: whole blood

X: Radiometer ABL 735

Y: epoc test

pCO₂	N	Sxx	Syy	Inter- cept	Slope	Syx	Xmin	Xmax	R	Mean Bias (mmHg)
Lab	77	1.5	0.8	1.6	0.924	1.97	27.6	101.5	0.987	-1.6

D. Limitations and Interferences

Exposure of the sample to air will affect pH, pCO₂, pO₂, TCO₂ and ionized calcium results due to the sample equilibration with the gas levels in the air, with pH and TCO₂ affected by the pCO₂ change³ and ionized calcium affected by the pH change⁸. Air contains less than 1 mmHg pCO₂ and about 150-180 mmHg pO₂. Do not introduce air bubbles into a collection device. If present, air bubbles should be removed immediately after collection.

Whole blood specimens should not be over-diluted with liquid anti-coagulants or other solutions used in therapies as this may alter results. Refer to 12.2.6 Sample Collection.

Interference testing⁷ was performed in-house on the epoc pCO₂ sensor. In each of these tests a whole blood specimen was aliquoted into two samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent

of the interferent. The $p\text{CO}_2$ bias between the mean of six replicates on both the control sample and the test sample with added interferent was calculated.

Clinically significant interfering substances are itemized below:

- Bromide will increase the $p\text{CO}_2$ by 0.19 mmHg/mM bromide.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 447 mg/dL ethanol, 1 mmol/L sodium pentothal, 4.3 mmol/L acetyl salicylate, 0.4 mmol/L ascorbate, 4.3 mmol/L salicylate, 2.2 mmol/L ibuprofen, 1.66 mmol/L acetaminophen, 2 mmol/L ammonium, 4 mmol/L lithium, 0.4 mmol/L iodide, 2.64 mmol/L propofol, 0.7 mmol/L cefotaxime, 0.16 mmol/L ampicillin, 1 mmol/L sodium perchlorate, 4.8 μM Zofran™, 2.5 mM N-acetylcysteine, 0.7 mM metronidazole, 719 $\mu\text{mol/L}$ (19.2 mg/dL) leflunomide, 1002 $\mu\text{mol/L}$ (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: 20 mmol/L NaCl, 8 mmol/L KCl, 3 mmol/L CaCl_2 , pH 6.9 to 7.7, +20 mmol/L bicarbonate, 10 mmol/L lactate, +20% PCV Hct, 3% to 11% total protein, 0.8g/dL lipids, 9.1 mmol/L cholesterol, 20 mmol/L β -hydroxybutyrate, 2mmol/L (24mg/dL) L-cysteine, 0.26 mmol/L bilirubin, +2 mmol/L phosphate, 20 to 600 mmHg $p\text{O}_2$.

E. References

1. CLSI. Blood Gas and pH Analysis and Related Measurements; Approved Guideline, CLSI C46-A2, Vol. 29, No. 8, Blood gas and pH analysis and related measurements- Approved Guideline, second edition, Wayne, Pennsylvania, USA, 2009.
2. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
3. M.G. Scott, V.A. LeGrys and J.S. Klutts, Chapter 27 of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
4. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
5. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
6. Radiometer ABL 735, Radiometer Medical ApS, Åkandevvej 21, DK-2700 Brønshøj, Denmark, "Radiometer" and "ABL" are registered trademarks of Radiometer Medical ApS.
7. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
8. D.B. Endres and R.K. Rude, Chapter 49 (p. 1901) of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
9. Stow, R.W, Baer, R.F., Randall, B.F., Rapid measurement of the tension of carbon dioxide in blood, Arch.Phys.Med.and Rehabil., 39, 646-650, 1957.
10. Severinghaus, J.W. and Bradley, A.F., Electrodes for blood $p\text{O}_2$ and $p\text{CO}_2$ determination, J.Appl.Physiol., 13, 515-520, 1958.
11. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
12. Reference Ranges Table 41-20 in Tietz Textbook of Clinical Chemistry, second edition, C.A. Burtis and E.R. Ashwood eds., Elsevier Saunders, Philadelphia, 1994.

12.5 pO_2

pO_2 is measured by amperometry using a membrane covered oxygen sensing cathode electrode. The oxygen reduction current is proportional to the dissolved oxygen concentration⁹.

12.5.1 Indications for Use

The pO_2 test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Measurement of pH, pCO_2 , pO_2 (blood gases) is used in the diagnosis and treatment of life-threatening acid-base disturbances.

12.5.2 Contents

Each Test Card incorporating a pO_2 test contains a sensing electrode with a oxygen permeable membrane, a reference electrode, a counter electrode and a calibrator fluid containing a known concentration of dissolved oxygen.

12.5.3 Traceability

Dissolved oxygen concentration values assigned to controls and calibrator fluids are traceable to NIST standards via commercially available certified gas standards.

12.5.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.5.5 Additional Information

Refer to Section 3 “epoc System Operation” in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 “Quality Assurance” in this manual for quality control requirements.

12.5.6 Measurement Range

	Measurement Range	Reference Range ³ , Arterial
pO_2	5 – 750 mmHg	83 – 108 mmHg
	0.7 – 100 kPa	11.1 – 14.4 kPa

Refer to Sections 5.2.2, 5.2.3, and 5.2.4 of CLSI C46-A2¹ for more information on sample types.

12.5.7 Temperature Correction

pO_2 is a temperature dependent quantity, measured at 37°C on the epoc System. The pO_2 value can be corrected to the Patient's temperature. Patient temperature is entered on the Test Information Page of the Reader Tab on the epoc Host (see Section 3 "epoc System Operation" in this manual).

The pO_2 at the Patient's temperature (T , °C) is calculated as follows¹

$$pO_2(T) = pO_2 \times 10^{\frac{5.49 \times 10^{-11} pO_2^{3.88} + 0.071}{9.71 \times 10^{-9} pO_2^{3.88} + 2.30} (T - 37)}$$

12.5.8 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2⁴ for method comparison studies, CLSI EP07-A2⁷ for interference studies and CLSI EP05-A2¹⁰ for precision studies.

A. Precision Data

In the precision data tables below, SD_{WR} denotes within run standard deviation and SD_T denotes total standard deviation.

In-house Precision 1: commercial aqueous blood gas and electrolyte controls run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 16 replicate measurements per lot per each control fluid level.

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_T	%CV
Level 1	mmHg	74.9	2.4	3.1	2.8	3.8
Level 3	mmHg	140.1	2.4	1.7	2.8	2.0

In-house Precision 2: commercial aqueous blood gas and electrolyte controls run in a 20 day precision study¹⁰ with 2 measurements each day per each control level. 4 manufactured lots, 6 different epoc Readers

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_T	%CV
Level 1	mmHg	78.4	1.9	2.5	2.6	3.3
Level 3	mmHg	141.2	1.8	1.3	2.2	1.6

In-house Precision 3: whole blood samples run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 12 replicates per each blood sample per lot.

Samples	Units	Mean	Mean SD_{WR}	%CV
Blood level 1	mmHg	38.0	2.2	5.9
Blood level 2	mmHg	70.0	2.4	3.5

Clinical Site Precision 1: 10 replicates of commercial aqueous blood gas controls run by operators of the epoc system at 3 different point-of-care sites. Each precision study employed from two (2) to four (4) different epoc Readers.

High pO_2 level commercial aqueous blood gas control

	Units	Mean	SD _{WR}	%CV
Operator 1	mmHg	136.3	4.1	3.0
Operator 2	mmHg	139.9	2.0	1.4
Operator 3	mmHg	138.1	3.1	2.2

Low pO_2 level commercial aqueous blood gas control

	Units	Mean	SD _{WR}	%CV
Operator 4	mmHg	67.5	2.3	3.5
Operator 5	mmHg	67.4	3.3	4.9
Operator 6	mmHg	70.1	3.2	4.6
Operator 7	mmHg	70.8	4.0	5.6

Clinical Site Precision 2: 10 replicates of different whole blood Patient samples run by different operators of the epoc system at different point-of-care sites. Each precision study employed 5 different epoc Readers.

		Units	Mean	SD _{WR}	%CV
Site 1	Operator 1	mmHg	28.6	1.7	6.0
	Operator 2	mmHg	32.9	1.8	5.5
Site 2	Operator 3	mmHg	33.9	1.2	3.5
	Operator 4	mmHg	30.0	1.5	5.0
	Operator 5	mmHg	40.1	1.2	3.1
Site 3	Operator 6	mmHg	61.8	3.5	5.6
	Operator 7	mmHg	74.6	2.9	3.9

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

This study was performed in-house on multiple whole blood samples with pO_2 values spanning the reportable range. Linearity is reported versus an in-house standard blood gas method with traceability to NIST standards.

	Test Range	Units	Slope	Intercept	R
pO_2	0.0 – 779.7	mmHg	1.010	4.425	0.998

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2⁴. In the method comparison statistics table, N is the number of Patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Clinical Site Method Comparison 1: In one hospital study, the epoc System was compared with the i-STAT 300⁵ in the lab (two test occasions), and then at three point-of-care sites.

Method Comparison Summary Statistics: whole blood

X: i-STAT 300 test

Y: epoc test

pO₂	Lab 1	Lab 2	POC 1	POC 2	POC 3	All
N	34	23	35	28	22	142
Sxx	2.6	4.3	3.2	6.2	2.7	4.6
Syy	1.7	3.5	3.0	2.9	2.6	2.7
Intercept	-6.5	-3.1	-1.3	0.3	-3.9	-1.7
Slope	1.142	1.006	1.083	1.041	1.090	1.053
Syx	8.5	4.5	4.5	4.9	4.2	6.6
Xmin	26.0	35.0	43.5	36.0	35.5	26.0
Xmax	174.5	226.5	185.0	187.5	166.0	226.5
R	0.977	0.995	0.995	0.990	0.994	0.978
Mean Bias (mmHg)						1.2

Clinical Site Method Comparison 2: In another hospital study, the epoc System was compared with the Radiometer ABL 735⁶ in the lab.

Method Comparison Summary Statistics: whole blood

X: Radiometer ABL 735

Y: epoc test

pO₂	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (mmHg)
Lab	77	3.4	3.7	-0.8	1.117	5.1	10.2	278.5	0.997	5

D. Limitations and Interferences

Exposure of the sample to air will affect pH, pCO₂, pO₂, TCO₂ and ionized calcium results due to the sample equilibration with the gas levels in the air, with pH and TCO₂ affected by the pCO₂ change¹ and ionized calcium affected by the pH change⁸. Air contains less than 1 mmHg pCO₂ and about 150-180 mmHg pO₂. Do not introduce air bubbles into a collection device. If present, air bubbles should be removed immediately after collection.

Whole blood specimens should not be over-diluted with liquid anti-coagulants or other solutions used in therapies as this may alter results. Refer to 12.2.6 Sample Collection.

Interference testing⁷ was performed in-house on the epoc pO_2 sensor. In each of these tests a whole blood specimen was aliquoted into two samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The pO_2 bias between the mean of six replicates on both the control sample and the test sample with added interferent was calculated.

Clinically significant interfering substances are itemized below:

- Metronidazole will cause an average bias of +4 mmHg/100 μ M metronidazole. Note that as per CLSI EP07-A2⁷, therapeutic levels of metronidazole range between 35 and 234 μ M.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 447 mg/dL ethanol, 1 mmol/L sodium pentothal, 4.3 mmol/L acetyl salicylate, 0.4 mmol/L ascorbate, 4.3 mmol/L salicylate, 1 mmol/L iodide, 2.2 mmol/L ibuprofen, 1.66 mmol/L acetaminophen, 2 mmol/L ammonium, 4 mmol/L lithium, 37.5 mmol/L bromide, 2.7% halothane, 2.64 mmol/L propofol, 0.7 mmol/L cefotaxime, 0.16 mmol/L ampicillin, 1 mmol/L sodium perchlorate, 4.8 μ M Zofran[™], 2.5 mM N-acetylcysteine, 719 μ mol/L (19.2 mg/dL) leflunomide, 1002 μ mol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: 20 mmol/L NaCl, 8 mmol/L KCl, 3 mmol/L CaCl₂, 10 to 120 mmHg pCO_2 , pH 6.9 to 7.7, +20 mmol/L bicarbonate, 10 mmol/L lactate, +20% PCV Hct, 3% to 11% total protein, 0.8g/dL lipids, 9.1 mmol/L cholesterol, 20 mmol/L β -hydroxybutyrate, 1 mmol/L L-cysteine, 0.26 mmol/L bilirubin, +2 mmol/L phosphate.

E. References

1. CLSI. Blood Gas and pH Analysis and Related Measurements; Approved Guideline, CLSI C46-A2, Vol. 29, No. 8, Blood gas and pH analysis and related measurements- Approved Guideline, second edition, Wayne, Pennsylvania, USA, 2009.
2. M.G. Scott, V.A. LeGrys and J.S. Klutts, Chapter 27 of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
3. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
4. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
5. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
6. Radiometer ABL 735, Radiometer Medical ApS, Åkandavej 21, DK-2700 Brønshøj, Denmark, "Radiometer" and "ABL" are registered trademarks of Radiometer Medical ApS.
7. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
8. D.B. Endres and R.K. Rude, Chapter 49 (p. 1901) of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
9. L.C. Clark Jr., Monitor and Control of Blood and Tissue Oxygen Tensions, Tr. AM. Soc. for Art. Int. Organs, 2:41, 1956
10. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.

12.6 Sodium (Na⁺)

Sodium is measured by potentiometry using an ion selective membrane electrode. The concentration of sodium ions is obtained from the measured potential using the Nernst equation. The epoc sodium measurement is an undiluted (direct) method. Values may differ from those obtained by dilutional (indirect) methods.¹

12.6.1 Indications for Use

The sodium test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Measurement of sodium is used in diagnosis and treatment of diseases involving electrolyte imbalance.

12.6.2 Contents

Each Test Card incorporating a sodium test contains a sodium sensing electrode with a sodium selective membrane, a reference electrode and a calibrator fluid containing a known concentration of sodium salts.

12.6.3 Traceability

Values of sodium ion concentration assigned to controls and calibrator fluids are traceable to NIST standards.

12.6.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.6.5 Additional Information

Refer to Section 3 "epoc System Operation" in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 "Quality Assurance" in this manual for quality control requirements.

12.6.6 Measurement Range

	Measurement Range	Reference Range ^{2,3}
Na⁺	85 – 180 mmol/L	138 – 146 mmol/L
	85 – 180 mEq/L	138 – 146 mEq/L

12.6.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2⁴ for method comparison studies, CLSI EP07-A2⁵ for interference studies and CLSI EP05-A2¹² for precision studies.

A. Precision Data

In the precision data tables below, SD_{WR} denotes within run standard deviation and SD_T denotes total standard deviation.

In-house Precision 1: Commercial aqueous blood gas and electrolyte controls run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 16 replicate measurements per lot per each control fluid level.

Aqueous Control	Units	Mean	SD _{WR}	%CV	SD _T	%CV
Level 1	mmol/L	113	0.9	0.8	1.2	1.1
Level 3	mmol/L	153	1.0	0.7	1.6	1.0

In-house Precision 2: Commercial aqueous blood gas and electrolyte controls run in a 20 day precision study¹² with 2 measurements each day per each control level. 4 manufactured lots, 6 different epoc Readers

Aqueous Control	Units	Mean	SD _{WR}	%CV	SD _T	%CV
Level 1	mmol/L	115	0.6	0.5	0.8	0.7
Level 3	mmol/L	153	0.7	0.5	1.0	0.6

In-house Precision 3: Whole blood samples run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 12 replicates per each blood sample per lot.

Whole Blood Samples	Units	Mean	Mean SD _{WR}	%CV
Blood level 1	mmol/L	147	0.9	0.6
Blood level 2	mmol/L	168	1.4	0.8

Clinical Site Precision 1: 10 replicates of commercial aqueous blood gas controls run by operators of the epoc system at 3 different point-of-care sites. Each precision study employed from 2 to 4 different epoc Readers.

High sodium level commercial aqueous blood gas control

	Units	Mean	SD _{WR}	%CV
Operator 1	mmol/L	158	1.3	0.8
Operator 2	mmol/L	155	0.8	0.5
Operator 3	mmol/L	157	1.3	0.8

Low sodium level commercial aqueous blood gas control

	Units	Mean	SD _{WR}	%CV
Operator 4	mmol/L	109	0.6	0.5
Operator 5	mmol/L	109	1.0	0.9
Operator 6	mmol/L	108	0.8	0.8
Operator 7	mmol/L	109	0.5	0.5

Clinical Site Precision 2: 10 replicates of different whole blood Patient samples run by different operators of the epoc system at different point-of-care sites. Each precision study employed 5 different epoc Readers.

		Units	Mean	SD _{WR}	%CV
Site 1	Operator 1	mmol/L	142	0.5	0.3
	Operator 2	mmol/L	143	1.5	1.0
Site 2	Operator 3	mmol/L	142	1.2	0.8
	Operator 4	mmol/L	143	0.8	0.6
	Operator 5	mmol/L	143	0.7	0.5
Site 3	Operator 6	mmol/L	141	0.7	0.5
	Operator 7	mmol/L	140	1.0	0.7

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

This study was performed in-house on multiple whole blood samples with sodium concentration spanning the reportable range. Linearity is reported versus an in-house standard ion selective electrode method with traceability to NIST standards.

	Test Range	Units	Slope	Intercept	R
Na+	80-190	mmol/L	0.973	3.8	0.9995

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2⁴. In the method comparison statistics table, N is the number of Patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Clinical Site Method Comparison 1: In one (1) hospital study, the epoc System was compared with the i-STAT 300⁶ in the lab (2 test occasions) then at three (3) point-of-care sites:

Method Comparison Summary Statistics: whole blood

X: i-STAT 300 test

Y: epoc test

Na+	Lab 1	Lab 2	POC 1	POC 2	POC 3	All	All*
N	34	24	35	27	22	142	156
Sxx	0.79	0.61	0.48	0.62	0.45	0.61	0.62
Syy	0.77	0.82	0.84	0.89	0.66	0.80	0.88
Intercept	22.2	8.4	5.3	27.9	28.9	8.8	-9.6
Slope	0.839	0.944	0.963	0.812	0.803	0.941	1.077
Syx	2.18	2.07	1.67	1.38	2.46	2.05	2.22
Xmin	125	123	130	135	130	123	123
Xmax	143	145	143	146	146	146	179
R	0.822	0.914	0.888	0.847	0.813	0.880	0.953
Mean Bias (mM)							0.77

*This data set includes Patient samples spiked with NaCl for extended data range.

Clinical Site Method Comparison 2: In another hospital study, the epoc System was compared with the Radiometer ABL 735⁷ in the lab.

Method Comparison Summary Statistics: whole blood

X: Radiometer ABL 735

Y: epoc test

Na+	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (mM)
Lab	77	0.78	0.79	19.1	0.881	1.81	131	160	0.924	2.3

D. Limitations and Interferences

Similar to other dry reagent methods, a decrease (increase) of total protein will increase (decrease) Na⁺ by 1.3 mM/(g/dL) versus a direct method. The epoc Na⁺ result tracks the reading of an indirect (dilutional) method^{1,8,9}.

Concordant with direct methods, hyperlipidemia does not affect the Na⁺ measurement^{8,9}. The effect of Intralipid was tested up to 5% (lipid vol)/(plasma vol) and was found to be clinically insignificant.

Whole blood specimens should not be over-diluted with liquid anti-coagulants or other solutions used in therapies as this may alter results. Refer to 12.2.6 Sample Collection.

Interference testing⁵ was performed in-house on the epoc sodium sensor. In each of these tests a whole blood specimen was aliquoted into two (2) samples. The test sample was spiked by addition of an interferent, while the control sample was spiked by the addition of the solvent of the interferent. The sodium bias between the mean of six (6) replicates on both the control sample and the test sample with added interferent was calculated.

Clinically significant interfering substances are itemized below:

- Use of evacuated collection tubes containing Na heparin may give erroneously high sodium results. The effect from the sodium heparin in these tubes is to increase the sodium result by approximately 1-2 mmol/L¹³;
- 20 mmol/L β -hydroxybutyrate will decrease Na⁺ by 3 mmol/L;
- 16 mmol/L bromide will increase sodium by 5 mmol/L;
- Samples contaminated with benzalkonium salts used as coatings for in-dwelling lines may cause significant elevation of sodium results¹⁰. For proper line-flushing procedures refer to CLSI H11¹¹;
- Teriflunomide will have no significant effect up to 720 μ mol/L (19.3 mg/dL), after which it will decrease sodium readings by as much as -0.67 mmol/L per 100 μ mol/L of teriflunomide. The therapeutic level for teriflunomide is in the range of 1-370 μ mol/L.¹⁴

Systematic errors in sodium readings may occur with over 20% hemodilution of plasma using solutions that are not consistent with the ionic characteristics of plasma, such as Normal Saline, Ringer's (Baxter Healthcare Corporation), and 10% Dextrose (Baxter Healthcare Corporation).

Hemodilution is associated with priming cardiopulmonary bypass pumps, plasma volume expansion, or other fluid administration therapies.

Such errors are prevented when physiologically balanced multi-electrolyte intravenous solutions containing low mobility anions that match the ionic characteristics of plasma, such as Plasma-Lyte™-A (Baxter Healthcare Corporation), Lactated Ringer's (Baxter Healthcare Corporation), Lactated Ringer's + 5% Dextrose injection (Baxter Healthcare Corporation), Plasbumin™-5 (Telacris Biotherapeutics), Pentaspan™ (Bristol-Myers Squibb), and Voluven™ (Fresenius Kabi) are used.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 447 mg/dL ethanol, 1 mmol/L sodium pentothal, 4.3 mmol/L acetyl salicylate, 0.4 mmol/L ascorbate, 4.3 mmol/L salicylate, 0.7 mmol/L iodide, 2.2 mmol/L ibuprofen, 1.66 mmol/L acetaminophen, 2 mmol/L ammonium, 4 mmol/L lithium, 3 μ mol/L dobutamine, 2.5 mmol/L tolbutamide, 2.64 mmol/L propofol, 0.7 mmol/L cefotaxime, 0.16 mmol/L ampicillin, 1 mmol/L sodium perchlorate, 4.8 μ M Zofran™, 2.5 mM N-acetylcysteine, 0.7 mM metronidazole, 719 μ mol/L (19.2 mg/dL) leflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: 8 mmol/L KCl, 3 mmol/L CaCl₂, 10 to 120 mmHg pCO₂, pH 6.9 to 7.7, +20 mmol/L bicarbonate, +20% PCV Hct, 9.1 mmol/L cholesterol, 2mmol/L (24mg/dL) L-cysteine, 0.26 mmol/L bilirubin, +2 mmol/L phosphate.

E. References

1. M.G. Scott, V.A. LeGrys and J.S. Klutts, Chapter 27 of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
2. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
3. B.E. Statland, Clinical Decision Levels for Lab Tests, Medical Economic Books, Oradell, NJ, 1987.
4. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
5. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
6. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
7. Radiometer ABL 735, Radiometer Medical ApS, Åkandavej 21, DK-2700 Brønshøj, Denmark, "Radiometer" and "ABL" are registered trademarks of Radiometer Medical ApS.
8. G. Dimeski, R. J. Barnett, "Effects of Total Plasma Protein Concentration on Plasma Sodium, Potassium and Chloride Measurements by an Indirect Ion Selective Electrode Measurement System", Critical Care and Resuscitation, 7, 12-15, 2005.
9. G.B. Levy, "Determination of Sodium with Ion-Selective Electrodes", Clinical Chemistry, 27, 1435-1437, 1981.
10. CLSI. Blood Gas and pH Analysis and Related Measurements; Approved Guideline, CLSI C46-A2, Vol. 29, No. 8, Blood gas and pH analysis and related measurements- Approved Guideline, second edition, Wayne, Pennsylvania, USA, 2009.
11. CLSI. Procedures for the Collection of Arterial Blood Specimens; Approved Standard, CLSI document H11-A4 (ISBN 1-56238-545-3), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
12. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
13. D. Young, E. Bermes, Jr, Chapter 2 of Tietz Textbook of Clinical Chemistry-Third Edition, C.A. Burtis and E.R. Ashwood, eds., W.B. Saunders Company, Philadelphia, 1999.
14. Chon W.J and Josephson M.A, "Leflunomide in renal transplantation", Expert Rev.Clin.Immunol., 7(3), p. 273-281, 2011.

12.7 Potassium (K⁺)

Potassium is measured by potentiometry using an ion selective membrane electrode. The concentration of potassium ions is obtained from the measured potential using the Nernst equation. The epoc potassium measurement is an undiluted (direct) method. Values may differ from those obtained by dilutional (indirect) methods.¹

12.7.1 Indications for Use

The potassium test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Measurement of potassium is used in diagnosis and treatment of diseases involving electrolyte imbalance.

12.7.2 Contents

Each Test Card incorporating a potassium test contains a potassium sensing electrode with a potassium selective membrane, a reference electrode, and calibrator fluid containing a known concentration of potassium salts.

12.7.3 Traceability

Values of potassium ion concentration assigned to controls and calibrator fluids are traceable to NIST standards

12.7.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.7.5 Additional Information

Refer to Section 3 "epoc System Operation" in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 "Quality Assurance" in this manual for quality control requirements.

12.7.6 Measurement Range

	Measurement Range	Reference Range ²
K⁺	1.5 – 12.0 mmol/L	3.5 – 4.5 mmol/L
	1.5 – 12.0 mEq/L	3.5 – 4.5 mEq/L

If a K result is higher than as per clinical status, the blood sample should be spun down and evaluated for hemolysis either visually or on a lab analyzer.

12.7.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2³ for method comparison studies, CLSI EP07-A2⁴ for interference studies and CLSI EP05-A2⁹ for precision studies.

A. Precision Data

In the precision data tables below, SD_{WR} denotes within run standard deviation and SD_T denotes total standard deviation.

In-house Precision 1: Commercial aqueous blood gas and electrolyte controls run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 16 replicate measurements per lot per each control fluid level.

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_T	%CV
Level 1	mmol/L	2.2	0.02	0.9	0.03	1.5
Level 3	mmol/L	6.7	0.06	0.9	0.07	1.1

In-house Precision 2: Commercial aqueous blood gas and electrolyte controls run in a 20 day precision study⁹ with two (2) measurements each day per each control level. four (4) manufactured lots, six (6) different epoc Readers

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_T	%CV
Level 1	mmol/L	2.2	0.02	1.0	0.03	1.2
Level 3	mmol/L	6.6	0.05	0.8	0.06	1.0

In-house Precision 3: Whole blood samples run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 12 replicates per each blood sample per lot.

Whole Blood Samples	Units	Mean	Mean SD_{WR}	%CV
Blood level 1	mmol/L	4.3	0.04	1.0
Blood level 2	mmol/L	6.2	0.05	0.8

Clinical Site Precision 1: 10 replicates of commercial aqueous blood gas controls run by operators of the epoc system at 3 different point-of-care sites. Each precision study employed from two (2) to four (4) different epoc Readers.

High potassium level commercial aqueous blood gas control.

	Units	Mean	SD_{WR}	%CV
Operator 1	mmol/L	6.8	0.05	0.7
Operator 2	mmol/L	6.7	0.06	0.9
Operator 3	mmol/L	6.7	0.09	1.3

Low potassium level commercial aqueous blood gas control.

	Units	Mean	SD_{WR}	%CV
Operator 4	mmol/L	2.0	0.01	0.6
Operator 5	mmol/L	2.0	0.03	1.6
Operator 6	mmol/L	2.0	0.05	2.5
Operator 7	mmol/L	2.0	0.02	1.0

Clinical Site Precision 2: 10 replicates of different whole blood Patient samples run by different operators of the epoc system at different point-of-care sites. Each precision study employed 5 different epoc Readers.

		Units	Mean	SD _{WR}	%CV
Site 1	Operator 1	mmol/L	4.0	0.05	1.3
	Operator 2	mmol/L	4.0	0.00	0.0
Site 2	Operator 3	mmol/L	3.7	0.00	0.0
	Operator 4	mmol/L	3.8	0.03	0.8
	Operator 5	mmol/L	3.7	0.03	0.9
Site 3	Operator 6	mmol/L	3.6	0.03	0.9
	Operator 7	mmol/L	4.1	0.05	1.2

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

This study was performed in-house on multiple whole blood samples with potassium concentration spanning the reportable range. Linearity is reported versus an in-house standard ion selective electrode method with traceability to NIST standards.

	Test Range	Units	Slope	Intercept	R
K+	1.5-12	mmol/L	1.006	0.03	0.9995

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2³. In the method comparison statistics table, N is the number of Patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Clinical Site Method Comparison 1: In one hospital study, the epoc System was compared with the i-STAT 300⁵ in the lab (two test occasions), and then at three (3) point-of-care sites.

Method Comparison Summary Statistics: whole blood

X: i-STAT 300 test

Y: epoc test

K+	Lab 1	Lab 2	POC 1	POC 2	POC 3	All	All*
N	34	24	35	27	22	142	146
Sxx	0.040	0.061	0.040	0.061	0.030	0.047	0.048
Syy	0.043	0.052	0.045	0.045	0.045	0.046	0.049
Intercept	-0.164	-0.144	-0.171	-0.134	0.134	-0.044	-0.018
Slope	1.056	1.042	1.051	1.057	0.971	1.021	1.013
Syx	0.088	0.114	0.057	0.077	0.114	0.094	0.094
Xmin	2.5	3.0	2.6	2.9	3.3	2.5	2.5
Xmax	6.1	4.8	5.1	4.9	6.7	6.7	7.8
R	0.991	0.979	0.993	0.993	0.988	0.989	0.993
Mean Bias (mM)							0.04

*This data set includes Patient samples spiked with KCl for extended data range.

Clinical Site Method Comparison 2: In another hospital study, the epoc System was compared with the Radiometer ABL 735⁶ in the lab.

Method Comparison Summary Statistics: whole blood

X: Radiometer ABL 735

Y: epoc test

K+	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (mM)
Lab	77	0.057	0.044	-0.073	1.026	0.090	2.4	7.1	0.996	0.04

D. Limitations and Interferences

Sample hemolysis will cause elevated potassium values. Improper sample collection technique may cause variation in potassium values due to hemolysis¹.

Whole blood specimens should not be over-diluted with liquid anti-coagulants or other solutions used in therapies as this may alter results. Refer to 12.2.6 Sample Collection.

Interference testing⁴ was performed in-house on the epoc potassium sensor. In each of these tests a whole blood specimen was aliquoted into two samples. The test sample was spiked by addition of an interferent, while the control sample was spiked by the addition of the solvent of the interferent. The potassium bias between the mean of six (6) replicates on both the control sample and the test sample with added interferent was calculated.

Clinically significant interfering substances are itemized below:

- Samples contaminated with benzalkonium salts used as coatings for in-dwelling lines may cause significant elevation of potassium results⁷. For proper line-flushing procedures refer to CLSI H11-A4⁸.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 447 mg/dL ethanol, 1 mmol/L sodium pentothal, 4.3 mmol/L acetyl salicylate, 0.4 mmol/L ascorbate, 4.3 mmol/L salicylate, 0.7 mmol/L iodide, 2.2 mmol/L ibuprofen, 1.66 mmol/L acetaminophen, 2 mmol/L ammonium, 4 mmol/L lithium, 38 mmol/L bromide, 3 µmol/L dobutamine, 2.5 mmol/L tolbutamide, 2.64 mmol/L propofol, 0.7 mmol/L cefotaxime, 0.16 mmol/L ampicillin, 1 mmol/L sodium perchlorate, 4.8 µM Zofran™, 2.5 mM N-acetylcysteine, 0.7 mM metronidazole, 719 µmol/L (19.2 mg/dL) leflunomide, 1002 µmol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: 20 mmol/L NaCl, 3 mmol/L CaCl₂, 10 to 120 mmHg pCO₂, pH 6.9 to 7.7, +20 mmol/L bicarbonate, 10 mmol/L lactate, +20% PCV Hct, 3% to 11% total protein, 0.8g/dL lipids, 9.1 mmol/L cholesterol, 20 mmol/L β-hydroxybutyrate, 2mmol/L (24mg/dL) L-cysteine, 0.26 mmol/L bilirubin, +2 mmol/L phosphate.

E. References

1. M.G. Scott, V.A. LeGrys and J.S. Klutts, Chapter 27 of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
2. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
3. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
4. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
5. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
6. Radiometer ABL 735, Radiometer Medical ApS, Åkandavej 21, DK-2700 Brønshøj, Denmark, "Radiometer" and "ABL" are registered trademarks of Radiometer Medical ApS.
7. CLSI. Blood Gas and pH Analysis and Related Measurements; Approved Guideline, CLSI C46-A2, Vol. 29, No. 8, Blood gas and pH analysis and related measurements- Approved Guideline, second edition, Wayne, Pennsylvania, USA, 2009.
8. CLSI. Procedures for the Collection of Arterial Blood Specimens; Approved Standard, CLSI document H11-A4 (ISBN 1-56238-545-3), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
9. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.

12.8 Ionized Calcium (Ca⁺⁺)

*Note: **Ca⁺⁺** and **iCa** are equivalent analyte acronyms that stand for ionized calcium.*

Ionized calcium is measured by potentiometry using an ion selective membrane electrode. The concentration of calcium ions is obtained from the measured potential using the Nernst equation.

12.8.1 Indications for Use

The ionized calcium test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Measurement of ionized calcium is used in diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany.

12.8.2 Contents

Each Test Card incorporating an ionized calcium test contains a calcium ion sensing electrode with a calcium selective membrane, a reference electrode and a calibrator fluid containing a known concentration of calcium salts.

12.8.3 Traceability

Values of calcium ion concentration assigned to controls and calibrator fluids are traceable to NIST standards

12.8.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.8.5 Additional Information

Refer to Section 3 “epoc System Operation” in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 “Quality Assurance” in this manual for quality control requirements.

12.8.6 Measurement Range

	Measurement Range	Reference Range ¹
Ca⁺⁺	0.25 – 4.00 mmol/L	1.15 – 1.33 mmol/L
	1.0 – 16.0 mg/dL	4.6 – 5.3 mg/dL
	0.5 – 8.0 mEq/L	2.3 – 2.7 mEq/L

12.8.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2² for method comparison studies, CLSI EP07-A2³ for interference studies and CLSI EP05-A2¹¹ for precision studies.

A. Precision Data

In the precision data tables below, SD_{WR} denotes within run standard deviation and SD_T denotes total standard deviation.

In-house Precision 1: Commercial aqueous blood gas and electrolyte controls run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 16 replicate measurements per lot per each control fluid level.

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_T	%CV
Level 1	mmol/L	2.18	0.03	1.4	0.04	1.7
Level 3	mmol/L	0.66	0.01	1.5	0.01	1.9

In-house Precision 2: commercial aqueous blood gas and electrolyte controls run in a 20 day precision study¹¹ with 2 measurements each day per each control level. 4 manufactured lots, 6 different epoc Readers

Aqueous Control	Units	Mean	SD_{WR}	%CV	SD_T	%CV
Level 1	mmol/L	2.20	0.02	1.0	0.03	1.3
Level 3	mmol/L	0.67	0.01	1.3	0.01	1.8

In-house Precision 3: whole blood samples run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 12 replicates per each blood sample per lot.

Whole Blood Samples	Units	Mean	Mean SD_{WR}	%CV
Blood level 1	mmol/L	1.35	0.02	1.4
Blood level 2	mmol/L	2.20	0.03	1.2

Clinical Site Precision 1: 10 replicates of commercial aqueous blood gas controls run by operators of the epoc system at 3 different point-of-care sites. Each precision study employed from 2 to 4 different epoc Readers.

Low ionized calcium level commercial aqueous blood gas control

	Units	Mean	SD_{WR}	%CV
Operator 1	mmol/L	0.57	0.01	1.9
Operator 2	mmol/L	0.56	0.01	0.9
Operator 3	mmol/L	0.57	0.01	1.7

High ionized calcium level commercial aqueous blood gas control

	Units	Mean	SD_{WR}	%CV
Operator 4	mmol/L	1.53	0.02	1.3
Operator 5	mmol/L	1.53	0.02	1.5
Operator 6	mmol/L	1.55	0.03	1.7
Operator 7	mmol/L	1.56	0.02	1.2

Clinical Site Precision 2: 10 replicates of different whole blood Patient samples run by different operators of the epoc system at different point-of-care sites. Each precision study employed 5 different epoc Readers.

		Units	Mean	SD _{WR}	%CV
Site 1	Operator 1	mmol/L	1.20	0.02	1.5
	Operator 2	mmol/L	1.21	0.02	1.9
Site 2	Operator 3	mmol/L	1.19	0.02	1.7
	Operator 4	mmol/L	1.21	0.03	2.1
	Operator 5	mmol/L	1.20	0.02	1.6
Site 3	Operator 6	mmol/L	1.23	0.02	1.8
	Operator 7	mmol/L	1.24	0.02	1.9

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

This study was performed in-house on multiple whole blood samples with ionized calcium concentration spanning the reportable range. Linearity is reported versus an in-house standard ion selective electrode method with traceability to NIST standards.

	Test Range	Units	Slope	Intercept	R
Ca++	0.22 – 4.24	mmol/L	1.004	-0.004	0.999

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2². In the method comparison statistics table, N is the number of Patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Clinical Site Method Comparison 1: In one hospital study, the epoc System was compared with the i-STAT 300⁴ in the lab (two test occasions), and then at three point-of-care sites.

Method Comparison Summary Statistics: whole blood

X: i-STAT 300 test

Y: epoc test

Ca++	Lab 1	Lab 2	POC 1	POC 2	POC 3	All	All*
N	34	24	35	28	22	143	156
Sxx	0.016	0.019	0.014	0.017	0.015	0.016	0.016
Syy	0.011	0.014	0.017	0.014	0.015	0.014	0.015
Intercept	0.003	0.050	0.157	0.106	0.103	0.102	-0.026
Slope	0.980	0.953	0.851	0.925	0.923	0.908	1.021
Syx	0.025	0.033	0.020	0.016	0.024	0.029	0.031
Xmin	0.8	0.9	1.1	1.0	1.0	0.8	0.80
Xmax	1.4	1.6	1.3	1.3	1.3	1.6	2.20
R	0.974	0.961	0.891	0.978	0.939	0.943	0.985
Mean Bias (mM)							0.014

*This data set includes Patient samples spiked with CaCl₂ for extended data range.

Clinical Site Method Comparison 2: In another hospital study the epoc System was compared with the Radiometer ABL 735⁵ in the lab.

Method Comparison Summary Statistics: whole blood

X: Radiometer ABL 735

Y: epoc test

Ca++	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (mM)
Lab	77	0.023	0.016	-0.045	1.025	0.040	0.34	1.52	0.981	-0.017

D. Limitations and Interferences

Specimen choice, collection technique, anti-coagulant type and level as well as sample handling will affect the concentration of ionized calcium⁶.

Exposure of the sample to air will affect pH, $p\text{CO}_2$, $p\text{O}_2$, TCO_2 and ionized calcium results due to the sample equilibration with the gas levels in the air, with pH and TCO_2 affected by the $p\text{CO}_2$ change⁷ and ionized calcium affected by the pH change⁸. Air contains less than 1 mmHg $p\text{CO}_2$ and about 150-180 mmHg $p\text{O}_2$. Do not introduce air bubbles into a collection device. If present, air bubbles should be removed immediately after collection.

Whole blood specimens should not be over-diluted with liquid anti-coagulants or other solutions used in therapies as this may alter results. Refer to 12.2.6 Sample Collection.

Interference testing³ was performed in-house on the ionized calcium sensor. In each of these tests a whole blood specimen was aliquoted into two samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The ionized calcium bias between the mean of six replicates on both the control sample and the test sample with added interferent was calculated.

Clinically significant interfering substances are itemized below:

- 20 mmol/L β -hydroxybutyrate will decrease Ca^{++} by 0.038 mmol/L;
- 4.3 mmol/L salicylate or acetyl salicylate will decrease Ca^{++} by 0.06 mmol/L. Therapeutic range for salicylate is 0.1mM to 2 mM (1.4 mg/dL to 27.4 mg/dL)¹³;
- 10 mmol/L bromide will increase Ca^{++} by 0.05 mmol/L;
- 1 mmol/L sodium perchlorate will decrease Ca^{++} by 0.23 mmol/L. The therapeutic level for perchlorate is in the range of 100–1000 mg/dL. No effect has been observed in persons exposed at 0.5 mg/dL or below¹²;
- Leflunomide will have no significant effect up to a concentration of 130 $\mu\text{mol/L}$ (3.6 mg/dL), after which it will decrease Ca^{++} readings by as much as -0.03 mmol/L per 100 $\mu\text{mol/L}$ of leflunomide. The therapeutic level for leflunomide is in the range of 1–370 $\mu\text{mol/L}$ ¹⁴;
- Teriflunomide will have no significant effect up to a concentration of 75 $\mu\text{mol/L}$ (2.0 mg/dL), after which it will decrease Ca^{++} readings by as much as -0.074 mmol/L per 100 $\mu\text{mol/L}$ of teriflunomide. The therapeutic level for teriflunomide is in the range of 1–370 $\mu\text{mol/L}$ ¹⁴.

Samples contaminated with benzalkonium salts used as coatings for in-dwelling lines may cause significant elevation of ionized calcium results⁹. For proper line-flushing procedures refer to CLSI H11¹⁰.

Highly heparinized samples will decrease the iCa^{6} ; balanced heparin or low heparin collection tubes/syringes are recommended.

Systematic errors in ionized calcium readings may occur with over 20% hemodilution of plasma using solutions that are not consistent with the ionic characteristics of plasma, such as Normal Saline, Ringer's (Baxter Healthcare Corporation), and 10% Dextrose (Baxter Healthcare Corporation).

Hemodilution is associated with priming cardiopulmonary bypass pumps, plasma volume expansion, or other fluid administration therapies.

Such errors are prevented when physiologically balanced multi-electrolyte intravenous solutions containing low mobility anions that match the ionic characteristics of plasma, such as Plasma-Lyte™-A (Baxter Healthcare Corporation), Lactated Ringer's (Baxter Healthcare Corporation), Lactated Ringer's + 5% Dextrose injection (Baxter Healthcare Corporation), Plasbumin™-5 (Telacris Biotherapeutics), Pentaspan™ (Bristol-Myers Squibb), and Voluven™ (Fresenius Kabi) are used.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 447 mg/dL ethanol, 1 mmol/L sodium pentothal, 0.4 mmol/L ascorbate, 1 mmol/L iodide, 2.2 mmol/L ibuprofen, 1.66 mmol/L acetaminophen, 2 mmol/L ammonium, 4 mmol/L lithium, 3 $\mu\text{mol/L}$ dobutamine, 2.5 mmol/L tolbutamide, 1.34 mmol/L propofol, 0.7 mmol/L cefotaxime, 0.16 mmol/L ampicillin, 4.8 μM Zofran™, 2.5 mM N-acetylcysteine, 0.7 mM metronidazole.

The following levels of endogenous interferences were tested and found to be clinically insignificant: 20 mmol/L NaCl, 8 mmol/L KCl, 10 to 120 mmHg $p\text{CO}_2$, pH 6.9 to 7.7, +20 mmol/L bicarbonate, +20% PCV Hct, 0.8g/dL lipids, 9.1 mmol/L cholesterol, 2mmol/L (24mg/dL) L-cysteine, 0.26 mmol/L bilirubin, +2 mmol/L phosphate.

E. References

1. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
2. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
3. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
4. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
5. Radiometer ABL 735, Radiometer Medical ApS, Åkandevvej 21, DK-2700 Brønshøj, Denmark, "Radiometer" and "ABL" are registered trademarks of Radiometer Medical ApS.
6. CLSI. Ionized Calcium Determinations: Pre-collection Variables, Specimen Choice, Collection and Handling. Approved Guideline, CLSI document C31-A2 (ISBN 1-56238-436-8), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2001.
7. M.G. Scott, V.A. LeGrys and J.S. Klutts, Chapter 27 of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
8. D.B. Endres and R.K. Rude, Chapter 49 (p. 1901) of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
9. CLSI. Blood Gas and pH Analysis and Related Measurements; Approved Guideline, CLSI C46-A2, Vol. 29, No. 8, Blood gas and pH analysis and related measurements- Approved Guideline, second edition, Wayne, Pennsylvania, USA, 2009.
10. CLSI. Procedures for the Collection of Arterial Blood Specimens; Approved Standard, CLSI document H11-A4 (ISBN 1-56238-545-3), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
11. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
12. C. Goebel, M.B. Kruse, A. Engel, S.H. Lamm, "On the use of human data in assessing effects on human health: the case of perchlorate." *Annals of Epidemiology*, volume 14, issue 8, p. 607, September 2004.
13. Borthwick, G. et al., "Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism", *FASEB J.* 20, 2006, p. 2009 – 2016.
14. Chon W.J and Josephson M.A, "Leflunomide in renal transplantation", *Expert Rev.Clin.Immunol.*, 7(3), p. 273-281, 2011.

12.9 Chloride (Cl⁻)

Chloride is measured by potentiometry using an ion selective membrane electrode. The concentration of chloride ions is obtained from the measured potential using the Nernst equation.

12.9.1 Indications for Use

The Chloride test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Chloride measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of electrolyte and metabolic disorders.

12.9.2 Contents

Each Test Card incorporating a chloride test contains a chloride ion sensing electrode with a chloride selective membrane, a reference electrode and a calibrator fluid containing a known concentration of chloride salts.

12.9.3 Traceability

Values of chloride ion concentration assigned to controls and calibrator fluids are traceable to NIST standards

12.9.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.9.5 Additional Information

Refer to Section 3 "epoc System Operation" in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 "Quality Assurance" in this manual for quality control requirements.

12.9.6 Measurement Range

	Measurement Range	Reference Range ¹
Cl ⁻	65 – 140 mmol/L	98 – 107 mmol/L
	65 – 140 mEq/L	98 – 107 mEq/L

12.9.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2² for method comparison studies, CLSI EP07-A2³ for interference studies, CLSI EP05-A2⁴ for precision studies, and CLSI EP06-A⁸ for linearity studies.

A. Precision Data

Precision (CLSI EP05-A2⁴): Three card lots using at least 25 epoc Readers with replicate measurements were run in-house twice a day for twenty days for each fluid. In the precision data tables below, SD_{WD} denotes within-day standard deviation, SD_{DD} denotes day-to-day standard deviation, SD_T denotes total standard deviation, $\%CV_{WD}$ denotes within-day coefficient of variation, and $\%CV_T$ denotes total coefficient of variation.

Aqueous Control	Units	N	Mean	SD_{WD}	SD_{DD}	SD_T	$\%CV_{WD}$	$\%CV_T$
High level	mM	240	125.0	0.61	0.61	0.86	0.5%	0.7%
Low level	mM	240	76.9	0.35	0.18	0.39	0.5%	0.5%

Pooled Whole Blood Precision Data: One hundred forty five patient samples were run in duplicate with approximately equal numbers of venous, arterial and capillary samples. Pooled pair-wise precision was estimated over three concentration ranges.

Range	<90	90 - 112	≥112
N	20	98	27
Average Reading, mM	78	105	123
Pair Precision (SD), mM	0.4	0.7	1.2
%CV	0.5%	0.6%	1.0%

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

Whole Blood Linearity Study (CLSI EP06-A⁸): This study was performed in-house on multiple whole blood samples with *Chloride* values spanning the reportable range. Linearity is reported versus theoretical chloride values based on gravimetric mixtures of high and low chloride samples (as measured using an in-house standard method). Six card lots were used in this study.

Test Range	Slope	Intercept	R
65-144mM	0.968	3.08	0.9995

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2². In the method comparison statistics table, N is the number of patient specimens in the data set, S_{xx} and S_{yy} are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, S_{yx} is the standard error and R is the correlation coefficient.

Method comparison studies were performed at two hospitals. Venous samples were compared with 2 non-point-of-care systems (2 serum methods). Venous, arterial and capillary patient samples were compared with a whole blood point-of-care system.

Cl-	Non-POC Systems*	i-STAT 300†
N	95	155
Sxx	0.6	0.9
Syy	0.7	0.8
Slope	0.90	0.99
Intercept	9.62	0.07
Syx	2.2	1.9
Xmin	71	69
Xmax	142	139
R	0.97	0.99
Mean Bias at 112 mM	-1.4	-1.0

* Pooled venous sample data. Approximately equal number of samples versus Roche Cobas 6000⁶, Siemens Advia⁷

† Patient samples approximately equal numbers of venous, arterial and capillary samples versus i-STAT 300⁵

D. Limitations and Interferences

Interference testing³ was performed in-house on the epoc chloride sensor. In each of these tests a pooled human serum specimen was aliquoted into two (2) samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The chloride bias between the mean of six (6) replicates on both the control sample and the test sample with added interferent was calculated.

Unacceptable interference bias was defined as producing a significant error more than 5% of the time. The concentration of interfering substance considered as causing no clinically significant interference is defined as a bias (difference between the test and the control sample) of $\leq 3.5\%$ for chloride concentrations ≤ 125 mM and $\leq 5.9\%$ for chloride concentrations > 125 mM.

Clinically significant interfering substances are itemized below:

- β -Hydroxybutyrate will have no significant effect up to 8.27 mM (85.2 mg/dL) after which it will increase the chloride reading by up to 0.37 mM/mM β -hydroxybutyrate;
- Bromide will have no significant effect up to 1.63 mM (13.1 mg/dL) after which it will increase the chloride reading by up to 2.75 mM/mM bromide;
- Citrate will have no significant effect up to 2.79 mM (52.7 mg/dL) after which it will increase the chloride reading by up to 1.13 mM/mM citrate;
- N-acetylcysteine will have no significant effect up to 5.55 mM (90.5 mg/dL) after which it will decrease the chloride reading by up to 0.79 mM/mM N-acetylcysteine. It has been reported that 1 mM N-acetyl cysteine is therapeutically unattainable in plasma⁹. The therapeutic level for N-acetyl cysteine is 0.3 mM¹⁰;
- Salicylic acid will have no significant effect up to 1.67 mM (22.9 mg/dL) after which it will increase the chloride reading by up to 2.94 mM/mM salicylic acid. Therapeutic range for salicylate is 0.1mM to 2 mM (1.4 mg/dL to 27.4 mg/dL)¹¹;
- Thiocyanate will have no significant effect up to 0.89 mM (5.2 mg/dL) after which it will increase the chloride reading by up to 5.62 mM/mM thiocyanate.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 1.324 mmol/L (20 mg/dL) acetaminophen, 3.62 mmol/L (65.2 mg/dL) acetylsalicylic acid, 342 µmol/L (6.8 mg/dL) Na ascorbate, 3.4 µmol/L (0.1 mg/dL) EDTA, 71 µmol/L (1.7 mg/dL) methyldopa, 2.55 mmol/L (156 mg/dL) oxidized glutathione, 2.55 mmol/L (78 mg/dL) reduced glutathione, 920 µmol/L (6.96 mg/dL) hydroxyurea, 282 µmol/L (4 mg/dL) isoniazid (nydrazid), 0.8% (800 mg/dL) intralipid, 3 µmol/L (0.1 mg/dL) dobutamine, 5.87 µmol/L (0.1 mg/dL) dopamine, 86.8 mmol/L (400 mg/dL) ethanol, 105 µmol/L (0.44 mg/dL) fluoride, 133 µmol/L (0.4 mg/dL) formaldehyde, 55 mmol/L (990 mg/dL) glucose, 0.4 mmol/L (5 mg/dL) guaiacol, 3000 U/L heparin, 2.43 mmol/L (50 mg/dL) ibuprofen, 0.1 mmol/L (2.0 mg/dL) L-Dopa, 51.2 µmol/L (1.2 mg/dL) lidocaine, 248 µmol/L (6 mg/dL) thiopental, 2.37 mmol/L (64 mg/dL) tolbutamide, 2.99 mmol/L (38 mg/dL) iodide, 2.643 mmol/L (120 mg/dL) cefazolin, 1.46 mmol/L (81 mg/dL) ceftriaxone, 719 µmol/L, (19.2 mg/dL) leflunomide, 1002 µmol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: +342 µmol/L (+20.1mg/dL) bilirubin unconjugated, +342 µmol/L (+28.8 mg/dL) bilirubin conjugate, +382 µmol/L (+5.0 mg/dL) creatine, 109 mmHg CO₂, 15 mmHg CO₂, +40 mmol/L (+244 mg/dL) bicarbonate, pH > 8.0, pH < 6.8, +20% hematocrit, -20% hematocrit, <6% protein, >9% protein, 1.4 mmol/L (23.5 mg/dL) uric acid. 6.6 mmol/L (74 mg/dL) lactate, 131 mmHg O₂, 22 mmHg O₂, 0.25 mmol/L (2.9 mg/dL) proline, 1 µmol/L (0.01 mg/dL) sarcosine, 42.9 mmol/L (258 mg/dL) urea.

E. References

1. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
2. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
3. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
4. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
5. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
6. Roche Cobas, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
7. Siemens Advia, Siemens Healthcare Diagnostics, 1717 Deerfield Road, Deerfield, IL 60015-0778.
8. CLSI. Evaluation of the Linearity of Quantitative Measurement Procedures; Approved Guideline, CLSI document EP06-A (ISBN 1-56238-498-8), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2003.
9. S. Whillier, J.E. Raftos, B. Chapman, P.W. Kuchel, "Role of N-acetylcysteine and cystine in glutathione synthesis in human erythrocytes." Redox Report: Communications In Free Radical Research, 2009, vol. 14, issue 3, p 115.
10. P. Ventura, R. Panini, M. C. Pasini, G. Scarpetta, G. Salvioli, "N-Acetyl-Cysteine Reduces Homocysteine Plasma Levels After Single Intravenous Administration by Increasing Thiols Urinary Excretion." Pharmacological Research. Volume 40, Issue 4, October 1999, P. 345-350.
11. Borthwick, G. et al., "Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism", FASEB J. 20, (2006), p. 2009 – 2016.

12.10 Total Carbon Dioxide (TCO₂)

TCO₂ is a measurement based on a modified Henderson-Hasselbalch equation, using pH and $p\text{CO}_2$ ¹, and calibrated to match the International Federation of Clinical Chemistry (IFCC) Reference Measurement Procedure for Total Carbon Dioxide². Therefore, it is metrologically traceable to the IFCC TCO₂ reference method².

12.10.1 Indications for Use

The TCO₂ test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Total Carbon Dioxide measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of disorders associated with changes in body acid-base balance.

12.10.2 Contents

Each epoc Test Card incorporating a TCO₂ test contains a hydrogen ion sensing electrode, a $p\text{CO}_2$ sensing electrode, a reference electrode and a calibrator fluid containing a known concentration of carbon dioxide.

12.10.3 Traceability

TCO₂ concentration values assigned to controls and calibrator fluids are traceable to NIST standards.

12.10.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.10.5 Additional Information

Refer to Section 3 “epoc System Operation” in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 “Quality Assurance” in this manual for quality control requirements.

12.10.6 Measurement Range

	Units of Measure	Measurement Range	Reference Range ^{6,7}	
			Arterial	Venous
TCO ₂	mmol/L	5 – 50	22 – 29	23 – 30
	mEq/L			

12.10.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A3³ for method comparison studies, CLSI EP07-A2¹⁴ for interference studies, CLSI EP05-A3¹⁵ for precision studies, and CLSI EP06-A⁵ for linearity studies.

A. Precision Data

Precision (CLSI EP05-A3¹⁵): Four card lots using at least 11 epoc Readers with replicate measurements were run in-house twice a day for twenty days for each fluid. In the precision data tables below, SD_{WR} denotes within-run standard deviation, $\%CV_{WR}$ denotes within-run coefficient of variation, SD_T denotes total standard deviation, and $\%CV_T$ denotes total coefficient of variation.

Aqueous Control	Units	N	Mean	S_{WR}	$\%CV_{WR}$	SD_T	$\%CV_T$
High Level	mmol/L	320	30.7	0.82	2.7%	0.92	3.0%
Low Level	mmol/L	320	16.2	0.88	5.4%	1.02	6.3%

Pooled Whole Blood Precision Data: Over 500 patient tests were run in duplicate with approximately equal numbers of venous, arterial and capillary samples. Pooled pair-wise precision was estimated over two concentration ranges.

Range	≤ 40	> 40
N	524	23
Average Reading, mM	24.5	44.8
Pair Precision (SD), mM	0.6	1.0
$\%CV$	2.6%	2.2%

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

Whole Blood Linearity Study (CLSI EP06-A⁵): This study was performed in-house on multiple whole blood samples with TCO_2 values spanning the reportable range. Linearity is reported versus theoretical TCO_2 values based on gravimetric mixtures of high and low TCO_2 samples (as measured using an in-house standard method). Three (3) card lots were used in this study.

Test Range	Slope	Intercept	R
4-49 mmol/L	0.903	3.32	0.9997

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A3³. In the method comparison statistics table, N is the number of patient specimens in the data set, S_{xx} and S_{yy} are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, S_{yx} is the standard error and R is the correlation coefficient.

Method comparison studies were performed at three hospitals. Venous, arterial and capillary patient samples for a total of over 150 results for each blood type were compared with a whole blood point-of-care system.

TCO₂ [mM]	i-STAT CHEM8+*
N	574
Sxx	0.68
Syy	0.64
Slope	1.039
Intercept	-0.8
Syx	1.52
Xmin	7
Xmax	49
R	0.974
Mean Bias at 20 mM	0.0 ± 0.2

* Patient samples approximately equal numbers of venous, arterial and capillary samples versus i-STAT CHEM8+⁴.

D. Limitations and Interferences

Exposure of the sample to air will affect pH, $p\text{CO}_2$, $p\text{O}_2$, TCO_2 and ionized calcium results due to the sample equilibration with the gas levels in the air, with pH and TCO_2 affected by the $p\text{CO}_2$ change⁸ and ionized calcium affected by the pH change¹⁶. Air contains less than 1 mmHg $p\text{CO}_2$ and about 150-180 mmHg $p\text{O}_2$. Do not introduce air bubbles into a collection device. If present, air bubbles should be removed immediately after collection.

Whole blood specimens should not be over-diluted with liquid anti-coagulants or other solutions used in therapies as this may alter results. Refer to 12.2.6 Sample Collection.

Avoid delays when testing for TCO_2 . Delays in testing with exposure to air may cause TCO_2 to be under-estimated due to CO_2 escape. Delays in testing without exposure to air may cause TCO_2 to be over-estimated due to metabolic activity. Refer to 12.2.6 Sample Collection.

Interference testing¹⁴ was performed in-house on the epoc TCO_2 sensor. In each of these tests, a pooled human serum specimen was aliquoted into two (2) samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The TCO_2 bias between the mean of six (6) replicates on both the control sample and the test sample with added interferent was calculated.

Unacceptable interference bias was defined as producing a significant error more than 5% of the time. The concentration of interfering substance considered as causing no clinically significant interference is defined as a bias (difference between the test and the control sample) of ≤ 3.23 mmol/L for TCO_2 concentration ≤ 20 mmol/L and ≤ 2.95 mmol/L for TCO_2 concentration > 20 mmol/L.

Clinically significant interfering substances are itemized below:

- Samples contaminated with benzalkonium salts used as coatings for in-dwelling lines may cause significant decrease in TCO_2 results. For proper line-flushing procedures refer to CLSI H11-A4¹¹;
- Citrate will have no significant effect up to 11.8 mmol/L (347.0 mg/dL) after which it will increase the TCO_2 concentration by up to 0.24 mmol/L TCO_2 per mmol/L citrate;

- EDTA will have no significant effect up to 4.8 mmol/L (178.7 mg/dL) after which it will increase the TCO₂ concentration by up to 0.57 mmol/L TCO₂ per mmol/L EDTA;
- N-acetyl cysteine will have no significant effect up to 9.6 mmol/L (156.7 mg/dL) after which it will increase the TCO₂ concentration by up to 0.54 mmol/L TCO₂ per mmol/L N-acetyl cysteine. It has been reported that 1 mmol/L N-acetyl cysteine is therapeutically unattainable in plasma¹². The therapeutic level for N-acetyl cysteine is 0.3 mmol/L¹³.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 1.324 mmol/L (20mg/dL) acetaminophen, 2 mmol/L (21.6 mg/dL) Li acetoacetic acid, 3.62mmol/L (65.2 mg/dL) acetyl salicylic acid, 1 mmol/L (5.349 mg/dL) ammonium chloride, 342 µmol/L (6.8 mg/dL) Na ascorbate, 37.5 mmol/L (386 mg/dL) Na bromide, 2.643 mmol/L (125.9 mg/dL) Na cefazolin, 1.46 mmol/L (96.6 mg/dL) Na ceftriaxone, 5.87 µmol/L (0.1 mg/dL) dopamine HCl, 86.8 mmol/L (400 mg/dL) ethanol, 50 µmol/L (4.46 mg/dL) (Flaxedil™) gallamine triethiodide, 28 mmol/L (0.5 g/dL) glucose, 2.55 mmol/L (156 mg/dL) oxidized glutathione, 2.55 mM (78.4 mg/dL) reduced glutathione, 5 mmol/L (38 mg/dL) glycolic acid, 20 U/mL heparin, 2 mmol/L (15 mg/dL) hydroxyurea, 2.43 mmol/L (50 mg/dL) ibuprofen, (0.5%) 500 mg/dL intralipid, 1.3 mmol/L (19.5 mg/dL) Na iodide, 1 mmol/L (12 mg/dL) L-cysteine, 25 µmol/L (~0.5 mg/dL) L-Dopa, 3.2 mmol/L (13.5 mg/dL) lithium chloride, 6 mmol/L (210.8 mg/dL) Na metamazole, 2 mmol/L (90 mg/dL) methotrexate, 16.7 mmol/L (264 mg/dL) Nithiodote, 0.22 mmol/L (4 mg/dL) oxalate (K) monohydrate, 248 µmol/L (6.5 mg/dL) Na pentothal, 1 mmol/L (12.2 mg/dL) Na perchlorate, 4.34 mmol/L (69.5 mg/dL) Na salicylate, 1.72 mmol/L (16.7 mg/dL) K thiocyanate, 719 µmol/L (19.2 mg/dL) leflunomide, 1002 µmol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: 342 µmol/L (28.8 mg/dL) bilirubin conjugated, 428 µmol/L (25 mg/dL) bilirubin unconjugated, Hct 20% to 60% PCV, 20 mmol/L (252 mg/dL) β-hydroxybutyrate, 6.6 mmol/L (74 mg/dL) lactate, 3.5% to 10% total protein, 1.4 mmol/L (23.5 mg/dL) uric acid.

E. References

1. A.H. Maas, P.Rispens, O.Siggaard-Andersen, W.G. Zijlstra, "On the reliability of Henderson-Hasselbalch equation in routine clinical acid-base chemistry", *Ann. Clin. Biochem.*, 21, 26-39, 1984.
2. IFCC 2001/3, "Reference Measurement Procedure for Substance Concentration Determination of Total Carbon Dioxide in Blood, Plasma or Serum," *Clin Chem Lab Med*, 39(3), 2001.
3. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline-Second Edition, CLSI document EP09-A3 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2013.
4. i-STAT CHEM8+, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
5. CLSI. Evaluation of the Linearity of Quantitative Measurement Procedures; Approved Guideline, CLSI document EP06-A (ISBN 1-56238-498-8), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2003.
6. B.E. Statland, *Clinical Decision Levels for Lab Tests*, Medical Economic Books, Oradell, NJ, 1987.

7. Pruden E.L., Siggaard-Andersen O., and Tietz N.W., Chapter 30 (Blood Gases and pH), of Tietz Textbook of Clinical Chemistry, Second Edition, ed. C.A. Burtis and E.R. Ashwood. W.B. Saunders Company, Philadelphia, 1994.
8. M.G. Scott et al, "Electrolytes and Blood Gases", Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th Ed, Ed. C.A. Burtis, E.R. Ashwood, D.E. Bruns, Page 991, 2006.
9. Gambino et al., "The measurement of CO₂ content with the autoanalyzer", Am.J.Clin Path, 45, p. 406, 1966.
10. Ungerer et al., "Discordance between measured and calculated total carbon dioxide", Clin.Chem., 36 (12), p. 2093-2096, 1990.
11. CLSI. Procedures for the Collection of Arterial Blood Specimens; Approved Standard, CLSI document H11-A4 (ISBN 1-56238-545-3), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
12. Whillier S., Raftos J.E., Chapman B., Kuchel P.W. (2009). Role of N-acetylcysteine and cystine in glutathione synthesis in human erythrocytes. Redox Report: Communications in Free Radical Research, 14(3), 115.
13. Ventura P., Panini R., Pasini M.C., Scarpetta G., Salvioli G. (1999). N-Acetyl Cysteine Reduces Homocysteine Plasma Levels After Single Intravenous Administration by Increasing Thiols Urinary Excretion. Pharmacological Research. 40(4), 345-350.
14. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
15. CLSI. Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline-Third Edition, CLSI document EP05-A3 (1-56238-967-X), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2014.
16. D.B. Endres and R.K. Rude, Chapter 49 (p. 1901) of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.

12.11 Glucose (Glu)

Glucose is measured by amperometry¹. The sensor comprises an immobilized enzyme first layer coated onto a gold electrode of the electrode module, with a diffusion barrier second layer. The glucose oxidase enzyme is employed to convert glucose to hydrogen peroxide,

Glucose Oxidase



and then uses an amperometric sensor to detect the enzymatically produced hydrogen peroxide. Peroxide detection is by redox mediated (ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt), horseradish peroxidase (HRP) catalyzed, reduction on a gold electrode.



The reduction current is proportional to the concentration of glucose in the test fluid.

The epoc Glucose result is reported as **plasma equivalent**² glucose concentration.

12.11.1 Indications for Use

The Glucose test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, idiopathic hypoglycemia and of pancreatic islet cell tumors.

12.11.2 Contents

Each Test Card incorporating a Glucose test contains a sensing electrode with a redox mediated enzymatic membrane covered with an oxygen permeable diffusion layer, a reference electrode, a counter electrode and a calibrator fluid containing a known concentration of glucose.

12.11.3 Traceability

Glucose concentration values assigned to controls and calibrator fluids are traceable to NIST standards.

12.11.4 Sample Collection

Refer to 12.2.6 Sample Collection.

As per Tietz¹³, capillary blood samples exhibit higher glucose than venous blood samples, by 2-5mg/dL in fasting patients and by 20% to 25% after a glucose load.

After the sample collection, glucose decreases in blood as a result of glycolysis by about 6% per hour¹³, and by as much as 13% per hour¹⁴

Always test immediately using Li or Na heparin as the anticoagulant or using no anticoagulant.

Do not use NaF or potassium oxalate as preservative.

12.11.5 Additional Information

Refer to Section 3 “epoc System Operation” in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 “Quality Assurance” in this manual for quality control requirements.

12.11.6 Measurement Range

	Measurement Range	Reference Range ³
Glucose	1.1 – 38.5 mmol/L	4.1 – 5.5 mmol/L
	20 - 700 mg/dL	74 – 100 mg/dL
	0.20 -7.00 g/L	0.74 – 1.00 g/L

12.11.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2⁴ for method comparison studies, CLSI EP07-A2⁵ for interference studies and CLSI EP05-A2⁶ for precision studies.

A. Precision Data

In the precision data tables below, SD_{WR} denotes within run standard deviation and SD_T denotes total standard deviation.

In-house Precision 1: commercial aqueous blood gas and electrolyte controls run on 5 sequential manufactured lots using at least 8 different epoc Readers, with 16 replicate measurements per lot per each control fluid level.

Aqueous Control	Units	Mean	SD _{WR}	%CV	SD _T	%CV
Level 3	mg/dL	51.1	1.2	2.3	1.6	3.1
Level 1	mg/dL	242.6	5.5	2.3	6.0	2.5

In-house Precision 2: commercial aqueous blood gas and electrolyte controls run in a 20 day precision study with 2 measurements each day per each control level for each of 4 manufactured lots using 6 different epoc Readers

Aqueous Control	Units	Mean	SD _{WR}	%CV	SD _T	%CV
Level 3	mg/dL	50.2	1.1	2.2	1.2	2.3
Level 1	mg/dL	241.9	4.7	2.0	5.5	2.3

In-house Precision 3: whole blood samples run on 5 sequential manufactured lots using at least 8 different epoc Readers, with 12 replicates per each blood sample per lot.

Whole Blood Samples	Units	Mean	Mean SD _{WR}	%CV
Blood level 1	mg/dL	72.3	1.2	1.5
Blood level 2	mg/dL	216.9	5.8	2.7

In-house Precision 4: whole blood samples were spiked at five levels of glucose and were tested with 100 replicates per each blood sample; each sample was tested within 12 minutes in two runs; each run was performed simultaneously on 50 different epoc Readers; a mix of four manufactured lots were included in this test.

Whole Blood Samples	Units	Mean	Mean SD	%CV
Blood level 1	mg/dL	22.5	1.2	5.4
Blood level 2	mg/dL	123.7	3.0	2.4
Blood level 3	mg/dL	215.9	8.5	3.9
Blood level 4	mg/dL	311.8	13.1	4.2
Blood level 5	mg/dL	548.3	17.6	3.2

Clinical Site Precision 1: 12 replicates of venous blood where glycolysis was allowed for a certain period of time was run by four different operators of the epoc system in a clinical environment. Each precision study employed 6 different epoc Readers.

Low glucose level blood

	Units	Mean	SD _{WR}	%CV
Operator 1	mg/dL	42.8	1.9	4.4
Operator 2	mg/dL	43.2	1.8	4.3
Operator 3	mg/dL	41.6	1.6	3.8
Operator 4	mg/dL	50.0	1.1	2.2

Clinical Site Precision 2: 12 replicates of venous blood spiked with glucose was run by four different operators of the epoc system in a clinical environment. Each precision study employed 6 different epoc Readers.

High glucose level blood

	Units	Mean	SD _{WR}	%CV
Operator 5	mg/dL	242.8	6.6	2.7
Operator 6	mg/dL	229.0	5.3	2.3
Operator 7	mg/dL	233.4	6.8	2.9
Operator 8	mg/dL	228.5	7.0	3.1

Clinical Site Precision 3: 10-12 replicates of commercial aqueous blood gas, electrolytes and metabolites controls were run by operators of the epoc system at 2 different point-of-care sites. Each precision study employed 5-6 different epoc Readers.

Low glucose level commercial aqueous blood gas electrolyte and metabolite control

	Units	Mean	SD _{WR}	%CV
Operator 1	mg/dL	48.0	1.5	3.2
Operator 2	mg/dL	46.6	1.0	2.1

Medium glucose level commercial aqueous blood gas electrolyte and metabolite control

	Units	Mean	SD _{WR}	%CV
Operator 3	mg/dL	109.7	3.6	3.3
Operator 4	mg/dL	106.8	1.8	1.7

High glucose level commercial aqueous blood gas electrolyte and metabolite control

	Units	Mean	SD _{WR}	%CV
Operator 5	mg/dL	258.9	9.0	3.5
Operator 6	mg/dL	256.9	2.3	0.9

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

This study was performed in-house on multiple whole blood samples with *Glucose* values spanning the reportable range.

	Test Range	Units	Slope	Intercept	R
Glu	16.6 – 818.9	mg/dL	0.993	5.762	0.996

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2⁴. In the method comparison statistics table, N is the number of Patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Clinical Site Method Comparison 1: In one hospital study, the epoc System was compared with the i-STAT 300⁷ in the lab and at one point-of-care site.

Method Comparison Summary Statistics: whole blood

X: i-STAT 300 CG8 cartridges test

Y: epoc test

Glu	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (%)
All	80	0.93	3.4	-2.2	1.031	5.6	20.0	605.5	0.9995	- 0.36%

The precision in whole blood was assessed from the pooling of within method pairs from the method comparison data. This is shown in the table below.

Glucose [mg/dL]			
Range	20 – 70	70 – 200	200 – 700
N	10	59	11
Average Reading	44.8	116.4	383.8
Pair Precision (SD)	0.80	2.44	7.08
%CV	1.8%	2.1%	1.8%

Clinical Site Method Comparison 2: In another hospital study, the epoc System was compared simultaneously with the Roche-Hitachi⁸ instrument in the lab and with i-STAT 300⁷. The summaries are presented in the tables below.

Method Comparison Summary Statistics: whole blood

X: Roche-Hitachi P800-D2400 test

Y: epoc test

Glu	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (%)
All	73	-	3.6	-0.2	0.971	3.0	23.0	546.0	0.998	-3.15%

Method Comparison Summary Statistics: whole blood

X: i-STAT 300 G cartridges test

Y: epoc test

Glu	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (%)
All	80	3.25	4.25	-1.33	1.003	4.45	22.5	517.5	0.999	-1.74%

The precision in whole blood was assessed from the pooling of within method pairs from the method comparison data. This is shown in the table below.

Glucose [mg/dL]			
Range	20 – 70	70 – 200	200 – 700
N	16	53	11
Average Reading	53.5	113.4	299.0
Pair Precision (SD)	1.32	3.18	8.73
%CV	2.47%	2.81%	2.92%

D. Consolidated Method Comparison Study Focusing on Low End Glucose Range

We evaluated the performance of the epoc glucose sensor in the low end range of glucose concentrations on Patient samples in clinical settings including at the point of care at several different hospitals. The results shown below include method comparison data against i-STAT⁷ (whole blood method), ABL 800 Flex⁹ (whole blood method), Roche-Hitachi⁸ (plasma method), and J&J¹² (plasma method). We supplemented the above mentioned clinical results with an in-house full duplicate method comparison⁴ against i-STAT⁷ and ABL705⁹.

In this study high hematocrit blood samples were prepared by removing half of the plasma volume from a venous sample that was allowed to glycolyse. The hematocrit of these specimens was tested by micro-centrifugation method¹¹ and found to be ~62%, i.e. characteristic to the upper range of the neonatal blood¹⁰. After the glucose reached ~20 mg/dL, it was spiked to cover uniformly the low range glucose, i.e. 20-80 mg/dL specific to neonatal population¹⁰. One sample was treated with Hexokinase, NADH- β and ATP in order to obtain a zero glucose concentration.

The data was processed as per CLSI EP09-A2 recommendations⁴. The correlation plot and bias plot are presented in the figures below. The test results versus the various reference instruments (X) are color coded.

epoc Low End Study	All points	Lab (plasma)	i-STAT	ABL	Roche	J&J
N	78	11	40	27	9	2
Sxx	1.0		0.6	1.6		
Syy	1.1	1.4	1.1	1.0	1.5	0.7
Intercept	-0.2	1.1	1.0	-2.2	0.8	
Slope	0.984	0.936	0.992	0.990	0.942	
Syx	2.9	2.1	2.55	2.16	2.21	
Xmin	1.5	23.0	20	1.5	23	25
Xmax	63.0	63.0	60	53	63	25
R	0.973	0.980	0.974	0.985	0.973	
Decision Level	40	40	40	40	40	
Bias	-0.8	-1.4	0.7	-2.6	-1.52	
Bias 95% Conf. Hi	-0.3	-0.5	1.3	-1.9	-0.18	
Bias 95% Conf. Lo	-1.3	-2.3	0.1	-3.3	-2.86	

Method Comparison Summary Statistics: whole blood


X (blue circles): i-Stat 300 G cartridges (whole blood) test

X (green squares): Roche Hitachi Lab (plasma) test

X (red diamonds): ABL 705 (whole blood) test


X (yellow triangles): J&J Lab (plasma) test

Y: epoc test



Low end glucose range, correlation plot versus various comparative instruments

Low end glucose range, bias plot versus various comparative instruments



E. Method Comparison Study Focusing on Capillary Blood Specimens

We evaluated the performance of the epoc tests on authentic capillary blood specimens in clinical settings at the point of care. The comparative method used i-STAT 300⁷ analyzers with CG8 cartridges and Radiometer CLINITUBE capillaries. Comparison testing was performed at four (4) locations: NICU, Well-baby Nursery, and two (2) different outpatient drawing areas. There were a total of 48 samples collected, of which 24 in full duplicate. Of the 48 samples, 12 were adult blood specimens and 36 were neonatal blood specimens.



The data was processed as per CLSI EP09-A2 recommendations⁴. The correlation plot and bias plot are presented in the figures below. The test results versus the patient age are color coded.

Method Comparison Summary Statistics: capillary blood

X: i-STAT 300 test

Y: epoc test

Glu	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R
All	48	1.13	1.80	5.1	0.935	2.42	42.5	147	0.9942



F. Limitations and Interferences

As per Tietz¹³, capillary blood samples exhibit higher glucose than venous blood samples, by 2 to 5 mg/dL in fasting patients and by 20% to 25% after a glucose load.

After the sample collection, glucose decreases in blood as a result of glycolysis by about 6% per hour¹³, and by as much as 13% per hour¹⁴.

Always test immediately using Li or Na heparin as the anticoagulant or using no anticoagulant.

Do not use NaF or potassium oxalate as preservative.

Interference testing⁵ was performed in-house on the epoc *glucose* sensor. In each of these tests a whole blood specimen was aliquoted into two samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The *glucose* bias between the mean of six replicates on both the control sample and the test sample with added interferent was calculated.

Clinically significant interfering substances are itemized below:

- Iodide will have no significant effect up to 28 μM (0.47 mg/dL KI), after which it will decrease glucose reading by as much as (-0.16 mg/dL)/ μM I-, i.e. (-9.5 mg/dL)/(mg/dL KI) ;
- Bromide will have no significant effect up to 28 mM (224 mg/dL NaBr), after which it will decrease glucose reading by (-0.23 mg/dL)/mM Br, i.e. (-0.029 mg/dL)/(mg/dL NaBr) ;
- N-acetylcysteine will have no significant effect up to 500 μM (8.2 mg/dL) N-acetylcysteine, after which it will decrease the glucose reading by (-7.2mg/dL)/mM N-acetylcysteine, i.e. (-0.44mg/dL)/(mg/dL N-acetylcysteine). It has been reported that 1 mM N-acetylcysteine is therapeutically unattainable in plasma¹⁵. The therapeutical level for N-acetylcysteine is 0.3 mM¹⁶;
- Flaxedil[™] (gallamine triethiodide) will have no significant effect up to 11 μM (1 mg/dL), after which it will decrease the glucose reading by (-0.27 mg/dL)/ μM gallamine triethiodide, i.e. (-3 mg/dL)/(mg/dL gallamine triethiodide) ;
- Thiocyanate will have no significant effect up to 1 mM (5.9 mg/dL KSCN), after which it will decrease the glucose reading with -1.7%/mM SCN, i.e. (-0.29 mg/dL)/(mg/dL KSCN) ;
- Uric acid will have no significant effect up to 700 μM (11.8 mg/dL), after which it will decrease the glucose reading by (-3.5 mg/dL)/mM uric acid, i.e. (-0.21 mg/dL)/(mg/dL uric acid);
- Mannose will have no significant effect up to 2 mM (36 mg/dL), after which it will increase the glucose reading by 2.12 mg/dL / (mM mannose), i.e. 0.059 mg/dL / (mg/dL mannose);
- Xylose will have no significant effect up to 3 mM (45 mg/dL), after which it will increase the glucose reading by 0.96 mg/dL / (mM xylose), i.e. 0.064mg/dL /(mg/dL xylose);
- Metamizole (dipyrone) will have no significant effect up to 0.194 mM, after which it will decrease the glucose reading by up to 3% / 0.1mM metamizole.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 1.66 mM (25 mg/dL) acetaminophen, 0.09 mmol/L (10 mg/dL) anidulafungin, 3.3 mmol/L (60 mg/dL) acetyl salicylate, 630 $\mu\text{mol/L}$ (12.5 mg/dL) Na ascorbate, 89.2 $\mu\text{mol/L}$ (4.5 mg/dL) clindamycin hydrochloride, 0.1 mmol/L (0.65 mg/dL) K cyanide, 6.15nmol/L (507 ng/dL) digoxin, 66 $\mu\text{mol/L}$ (2.2 mg/dL) dobutamine, 100 $\mu\text{mol/L}$ (1.9 mg/dL) dopamine HCl, 50 $\mu\text{mol/L}$ (~1 mg/dL) L-dopa, 9 mmol/L (263 mg/dL) EDTA, 12 $\mu\text{mol/L}$ (0.2 mg/dL) ephedrine, 87 mM (400 mg/dL) ethanol, 4.84 mmol/L (30 mg/dL) ethylene glycol, 1.78 $\mu\text{mol/L}$ (60 $\mu\text{g/dL}$) famotidine, 1 mmol/L (18 mg/dL) fructose, 181 $\mu\text{mol/L}$ (6 mg/dL) furosemide, 3.3 mmol/L (59 mg/dL) galactose, 238 $\mu\text{mol/L}$ (10 mg/dL) gentamicin, 4.5 $\mu\text{mol/L}$ (200 $\mu\text{g/dL}$) glipizide, 1.1 mmol/L (28.5 mg/dL) glucosamine, 2.55 mmol/L RBC oxidized glutathione, 2.55 mmol/L RBC reduced glutathione, 400 $\mu\text{mol/L}$ (5 mg/dL) guaiacol, 80U/mL heparin, 0.4 mmol/L (14.5 mg/dL) hydrocortisone, 2.5 mmol/L

(19 mg/dL) hydroxyurea, 292 µmol/L (4 mg/dL) Nydrazid™ (isoniazide), 48.6 µmol/L (1.76 mg/dL) levofloxacin, 1 mmol/L (34 mg/dL) linezolid, 13.3 mmol/L (479 mg/dL) maltose, 937.5 µmol/L (1500 mg/dL) icodextrin, 71 µmol/L (1.7 mg/dL) methyldopa, 77.4 µmol/L (2.9 mg/dL) 6α-methyl prednisolone, 0.7 mM (12 mg/dL) metronidazole, 17.4 µM (0.6 mg/dL) omeprazole, 102 µmol/L (2.4 mg/dL) procainamide, 4.22 µmol/L (0.12 mg/dL) promethazine hydrochloride, 37 µmol/L (1.2 mg/dL) quinidine, 1.67 µmol/L (40 µg/dL) salbutamol (albuterol), 4.34 mmol/L (60 mg/dL) salicylic acid, 1.96 µmol/L (60 µg/dL) sertraline, 413 µmol/L (10 mg/dL) sodium pentothal, 1 mmol/L (31 mg/dL) Tolinase™ (tolazamide), 2.37 mmol/L (64 mg/dL) tolbutamide, 69 µmol/L (10 mg/dL) vancomycin, 21.3 µmol/L (1 mg/dL) vitamin K1, 2.64 mmol/L (47 mg/dL) propofol, 0.7 mmol/L (334.2 mg/dL) cefotaxime, 0.16 mmol/L (59.4 mg/dL) ampicillin, 1 mmol/L (122.4 mg/dL) sodium perchlorate, 4.8 µM (1.75 mg/dL) Zofran™, 719 µmol/L (19.2 mg/dL) leflunomide, 1002 µmol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: +20 mmol/L (168 mg/dL) Na bicarbonate, +86 µmol/L (+7.3 mg/dL) bilirubin conjugated, +510 µmol/L (+30 mg/dL) bilirubin unconjugated, 13mM (503.1 mg/dL) cholesterol, 15 to 140 mmHg pCO₂, 2mmol/L (24mg/dL) L-cysteine, +20 mmol/L (+256 mg/dL) Na β-hydroxybutyrate, +20 mmol/L (+180 mg/dL) Na L-lactate, +0.8g/dL lipids, +59.2 µmol/L (+1.9 mg/dL) norepinephrine, pH 6.7 to 7.7, +20% PCV Hct, 3.4% to 10.4% total protein, 11.2mM (991 mg/dL) triglycerides.

G. References

1. P. D'Orazio, M.E. Meyerhoff, "Electrochemistry and Chemical Sensors", Chapter 4 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
2. P. D'Orazio et al, Approved IFCC recommendation on reporting results for blood glucose (abbreviated), Clin Chem 2005 51: 1573-1576
3. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
4. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
5. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
6. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
7. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
8. Roche-Hitachi are registered trademarks of F. Hoffman-La Roche Ltd., 4070 Basel, Switzerland.
9. Radiometer ABL 705 and ABL 800Flex, Radiometer Medical ApS, Åkandevvej 21, DK-2700 Brønshøj, Denmark, "Radiometer" and "ABL" are registered trademarks of Radiometer Medical ApS.

10. C. Rooks, "Points to consider for portable blood glucose monitoring devices intended for bedside use in the neonate nursery", Guidance to FDA publication No. 87-4224, 1996.
11. CLSI. Procedure for determining Packed Cell Volume by the Microhematocrit method; Approved Standard, third edition, CLSI document H07-A3 (ISBN 1-56238-413-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2000.
12. J&J VITROS DTII is a registered trademark of Ortho-Clinical Diagnostics, a Johnson&Johnson company, Raritan, NJ 08869, United States.
13. D.B. Sacks, Chapter 25 (p. 837) of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
14. Chapter 141, Blood Glucose of J. Michael McMillin, Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations, third edition. Boston: Butterworths; 1990.
15. S. Whillier, J.E. Raftos, B. Chapman, P.W. Kuchel, "Role of N-acetylcysteine and cysteine in glutathione synthesis in human erythrocytes." Redox Report: Communications In Free Radical Research, 2009, vol. 14, issue 3, p 115.
16. P. Ventura, R. Panini, M. C. Pasini, G. Scarpetta, G. Salvioli, "N-Acetyl-Cysteine Reduces Homocysteine Plasma Levels After Single Intravenous Administration by Increasing Thiols Urinary Excretion." Pharmacological Research. Volume 40, Issue 4, October 1999, P. 345-350.


12.12 Lactate (Lac)

Lactate is measured by amperometry¹. The sensor comprises an immobilized enzyme first layer coated onto a gold electrode of the electrode module, with a diffusion barrier second layer. The lactate oxidase enzyme is employed to convert lactate to hydrogen peroxide,

Lactate Oxidase



and then uses an amperometric sensor to detect the enzymatically produced hydrogen peroxide. Peroxide detection is by redox mediated (ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt), horseradish peroxidase (HRP) catalyzed, reduction on a gold electrode.



The reduction current is proportional to the concentration of lactate in the test fluid.

12.12.1 Indications for Use

The *Lactate* test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Lactate measurements are used to evaluate the acid-base status and are used in the diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).

12.12.2 Contents

Each test card incorporating a *Lactate* test contains a sensing electrode with a redox mediated enzymatic membrane covered with an oxygen permeable diffusion layer, a reference electrode, a counter electrode and a calibrator fluid containing a known concentration of lactate.

12.12.3 Traceability

Certified standard reference material for lactate is not available at present. Lactate values assigned to controls and calibration verification materials are traceable to a working calibrator prepared from Sodium L-Lactate from Sigma-Aldrich Co., Item Number 71718, >99% purity.

12.12.4 Sample Collection

Refer to 12.2.6 Sample Collection.

Collection of a satisfactory specimen for Lactate analysis requires special procedures to prevent changes in lactate both during and after blood is drawn¹¹.

As per Tietz¹¹, for venous samples, do not use a tourniquet or immediately remove the tourniquet before the draw. During exercise, Lactate may increase significantly within 10 seconds. Therefore, for relevant Lactate readings, the patients should be fasting and at rest for at least 2 hours. After sample collection, lactate rapidly increases in blood as a result of glycolysis by as much as 20% in 3 min and 70% in 30 min at 25°C.

Always test immediately using Li or Na heparin as the anticoagulant or using no anticoagulant. Do not use NaF or potassium oxalate as preservative.

12.12.5 Additional Information

Refer to Section 3 “epoc System Operation” in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 “Quality Assurance” in this manual for quality control requirements.

12.12.6 Measurement Range

	Measurement Range	Reference Range ² , Arterial	Reference Range ² , Venous
Lactate	0.30 – 20.00 mmol/L	0.36 – 0.75 mmol/L	0.56 – 1.39 mmol/L
	2.7 – 180.2 mg/dL	3.2 – 6.8 mg/dL	5.0 – 12.5 mg/dL
	0.03 – 1.80 g/L	0.03 – 0.07 g/L	0.05 – 0.12 g/L

12.12.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2³ for method comparison studies, CLSI EP07-A2⁴ for interference studies, CLSI EP06-A⁷ for linearity studies, and CLSI EP05-A2⁵ for precision studies.

A. Precision Data

In the precision data tables below, SD_{WD} denotes within-day standard deviation, SD_{DD} denotes day-to-day standard deviation and SD_T denotes total standard deviation.

In-house Precision (CLSI EP5-A): Four (4) card lots using at least 40 epoc Readers with replicate measurements were run in-house twice a day for twenty days for each fluid.

Aqueous Control	Units	N	Mean	SD _{WR}	SD _{DD}	SD _T	Total %CV
Level 1	mM	320	7.99	0.39	0.32	0.51	6.3
Level 3	mM	320	0.94	0.03	0.03	0.04	4.7

Aqueous Clinical Site Precision: 14-15 replicates of commercial aqueous blood gas, electrolytes and metabolites controls were run by potential end users of the epoc system at 2 different point-of-care sites. Each precision study employed at least 5 different epoc Readers. Three lots of cards were used.

		Aqueous Control	N	Units	Mean	SD	%CV
Site 1	Operator 1	Level 3	15	mM	0.95	0.031	3.3
	Operator 2	Level 3	15	mM	0.94	0.027	2.9
	Operator 3	Level 2	14	mM	2.88	0.05	1.8
	Operator 4	Level 2	15	mM	2.91	0.08	2.8
Site 2	Operator 1	Level 1	15	mM	7.34	0.57	7.8
	Operator 2	Level 1	15	mM	7.45	0.42	5.6

Blood Clinical Site Precision: 15 replicates of venous whole blood at two (2) different lactate concentrations were run by potential end users of the epoc system at two (2) different point-of-care sites. Each precision study employed at least five (5) different epoc Readers. Four (4) card lots were used in this study.

		Whole Blood Samples	N	Units	Mean	SD	%CV
Site 1	Operator 1	Blood Level 1	15	mM	10.24	0.62	6.0
	Operator 2	Blood Level 1	15	mM	10.27	0.34	3.3
Site 2	Operator 1	Blood Level 2	15	mM	2.77	0.07	2.7
	Operator 2	Blood Level 2	15	mM	2.67	0.12	4.7

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

Whole Blood Linearity Study (CLSI EP06-A⁷): This study was performed in-house on multiple whole blood samples with *Lactate* values spanning the reportable range. Linearity is reported versus theoretical lactate values based on gravimetric mixtures of high and low lactate samples. Four (4) card lots were used in this study.

Test Range	Slope	Intercept	R
0.3-20.1 mM	1.001	0.271	0.9995

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2³. In the method comparison statistics table, N is the number of Patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Method comparison studies were performed at two (2) hospitals. At one hospital, 126 venous samples were tested. At another hospital, both 73 arterial and 174 capillary samples were tested. Sample lactate concentrations on the comparison device varied from 0.57 to 14.57 mmol/L.

In these studies, the epoc System was compared with the i-STAT 300 analyzer⁶.

Method Comparison Summary Statistics: whole blood—venous, arterial, capillary

X: i-STAT CG4+ cartridges

Y: epoc test

Lac	epoc	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (%)
	i-STAT	373	0.215	0.530	0.132	0.967	0.948	0.48	19.95	0.985	2.75

D. Limitations and Interferences

Collection of satisfactory specimen for Lactate analysis requires special procedures to prevent changes in Lactate both during and after blood is drawn¹¹.

As per Tietz¹¹, for venous samples, do not use a tourniquet or immediately remove the tourniquet before the draw. During exercise, Lactate may increase significantly within 10 seconds. Therefore, for relevant Lactate readings, the patients should be fasting and at rest for at least 2 hours.

After the sample collection, lactate rapidly increases in blood as a result of glycolysis by as much as 20% in 3 min and 70% in 30 min at 25°C.

Always test immediately using Li or Na heparin as the anticoagulant or using no anticoagulant.

Do not use NaF or potassium oxalate as preservative.

Interference testing⁴ was performed in-house on the epoc lactate sensor. In each of these tests a pooled human serum specimen was aliquoted into two (2) samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The lactate bias between the mean of six (6) replicates on both the control sample and the test sample with added interferent was calculated.

Unacceptable interference bias was defined as producing a significant error more than 5% of the time.

Significant interfering substances are itemized below:

- Acetaminophen will have no significant effect up to 0.81 mM after which it will increase the lactate reading up to 306µM/mM Tylenol™ (acetaminophen). Because the therapeutic upper limit for acetaminophen is 0.20 mM, interfering levels of acetaminophen should only be encountered in overdose situations;
- Iodide will decrease the lactate reading up to -3.3 mM/mM of Iodide for an Iodide concentration under 0.3 mM. Above 0.3 mM Iodide, the Lactate bias will be a constant -1.0 mM;
- Bromide will have no significant effect up to 25.4 mM after which it will decrease the lactate reading up to 14.6µM/mM Bromide;
- Thiocyanate will have no significant effect up to 2.7 mM after which it will decrease the lactate reading by up to 96.6µM/mM thiocyanate;
- N-acetylcysteine will have no significant effect up to 3.7 mM after which it will decrease the lactate reading by up to 96.3µM/mM N-acetylcysteine. It has been reported that 1 mM N-acetylcysteine is therapeutically unattainable in plasma⁹. The therapeutical level for N-acetylcysteine is 0.3 mM¹⁰.

Ethylene glycol ingestion and metabolism has been shown to produce falsely elevated lactate measurements⁸. Ethylene glycol plus three metabolism products - Glycolic Acid, Glyoxylic Acid and Oxalic Acid - were tested for interference. Ethylene Glycol and Oxalic Acid do not interfere significantly.

- Glycolic Acid will have no significant effect up to 0.87 mM after which it will increase the lactate reading up to 142µM/mM glycolic acid;
- Glyoxylic Acid will have no significant effect up to 0.85 mM after which it will increase the lactate reading up to 373µM/mM glyoxylic acid.

The following levels of exogenous interferences were tested and found to be insignificant: 630µmol/L (12.5 mg/dL) Na ascorbate, 20 mmol/L (588 mg/dL) citrate, 100µmol/L (~2 mg/dL) L-dopa, 9 mmol/L (263 mg/dL) EDTA, 4.84 mmol/L (30 mg/dL) ethylene glycol, 105µmol/L (0.441 mg/dL) Na fluoride, 71µmol/L methyldopa, 2.55 mmol/L oxidized glutathione, 2.55 mmol/L reduced glutathione, 132µmol/L (1.0 mg/dL) hydroxyurea, 292µmol/L (4 mg/dL) Nydrazid™ (isoniazide), 81µmol/L (1.5 mg/dL) K oxalate, 0.037 mmol/L (1.2 mg/dL) quinidine, 2.64 mmol/L (47 mg/dL) propofol, 0.7 mmol/L (334.2 mg/dL) cefotaxime, 0.16 mmol/L (59.4 mg/dL) ampicillin, 1 mmol/L (122.4 mg/dL) sodium perchlorate, 3.7 mmol/L (603.8 mg/dL) N-acetylcysteine, 4.8 µM Zofran™, 0.7 mM metronidazole, 719 µmol/L (19.2 mg/dL) leflunomide, 1002 µmol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be insignificant: +342µmol/L (+29.0 mg/dL) bilirubin conjugated, +342µmol/L (+20.1 mg/dL) bilirubin unconjugated, +13 mmol/L (+503.1 mg/dL) cholesterol, 2mmol/L (24mg/dL) L-cysteine, +0.8g/dL lipids, pH (+0.4, -0.4), 3% to 10% total protein, 1.4 mM (+ 23.5 mg/dL) Uric Acid. Low hematocrit did not interfere down to a level of 21 % hematocrit and high hematocrit did not interfere up to a level of 61 % hematocrit. Triglycerides did not show significant interference up to a level of 37 mM (3274 mg/dL). *p*O₂ partial pressures below 20 mmHg (2.67kPa) may decrease lactate values.

E. References

1. P. D'Orazio, M.E. Meyerhoff, "Electrochemistry and Chemical Sensors", Chapter 4 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St.Louis, 2006.
2. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
3. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
4. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
5. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
6. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
7. CLSI. Evaluation of the Linearity of Quantitative Measurement Procedures; Approved Guideline, CLSI document EP06-A (ISBN 1-56238-498-8), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2003.
8. P.G. Brindley et al., "Falsely elevated point-of-care lactate measurement after ingestion of ethylene glycol", CMAJ, April 10, 2007, 176(8), p.1097
9. S. Whillier, J.E. Raftos, B. Chapman, P.W. Kuchel, "Role of N-acetylcysteine and cysteine in glutathione synthesis in human erythrocytes." Redox Report: Communications In Free Radical Research, 2009, vol. 14, issue 3, p 115.
10. P. Ventura, R. Panini, M. C. Pasini, G. Scarpetta, G. Salvioli, "N-Acetyl-Cysteine Reduces Homocysteine Plasma Levels After Single Intravenous Administration by Increasing Thiols Urinary Excretion." Pharmacological Research. Volume 40, Issue 4, October 1999, P. 345-350.
11. D.B. Sacks, Chapter 22 (p. 929) of Tietz Textbook of Clinical Chemistry-Second Edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, Philadelphia, 1994.

12.13 Blood Urea Nitrogen (BUN/Urea)

BUN/Urea is measured by potentiometry using an ammonium ion selective electrode coated onto a gold electrode, covered with an enzymatic membrane second layer. The urease enzyme is employed to convert urea to ammonium ions:



and then uses a potentiometric ion selective electrode to detect the enzymatically produced ammonium ion. The concentration of ammonium ions is obtained from the measured potential using the Nernst equation.

12.13.1 Indications for Use

The BUN/Urea test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Blood Urea Nitrogen (BUN/Urea) measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of certain renal and metabolic diseases.

12.13.2 Contents

Each test card incorporating a BUN/Urea test contains a BUN/Urea sensing electrode with an ammonium selective membrane covered with a gas permeable enzymatic layer, a reference electrode and calibrator fluid containing known concentration of urea.

12.13.3 Traceability

Values of BUN/Urea assigned to controls and calibrator fluids are traceable to NIST standards.

12.13.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.13.5 Additional Information

Refer to Section 3 “epoc System Operation” in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 “Quality Assurance” in this manual for quality control requirements.

12.13.6 Measurement Range

	Measurement Range	Reference Range ¹
BUN	3 – 120 mg/dL	8-26 mg/dL

	Measurement Range	Reference Range ¹
Urea	1.1 – 42.8 mmol/L	2.9 – 9.3 mmol/L
	7 – 257 mg/dL	17 – 56 mg/dL
	0.07 – 2.57 g/L	0.17 – 0.56 g/L

12.13.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A3² for method comparison studies, CLSI EP07-A2³ for interference studies, CLSI EP06-A⁴ for linearity studies, and CLSI EP05-A3⁵ for precision studies.

A. Precision Data

Precision (CLSI EP05-A3⁵): Four card lots using at least 11 epoc Readers with replicate measurements were run in-house twice a day for twenty days for each fluid. In the precision data tables below, SD_{WR} denotes within-run standard deviation, $\%CV_{WR}$ denotes within-run coefficient of variation, SD_T denotes total standard deviation, and $\%CV_T$ denotes total coefficient of variation.

Aqueous Control	Units	N	Mean	SD_{WR}	$\%CV_{WR}$	SD_T	$\%CV_T$
High Level	mg/dL	320	51.7	1.01	2.0%	1.16	2.3%
Low Level	mg/dL	320	7.1	0.30	4.2%	0.32	4.5%

Pooled Whole Blood Precision Data: Over 430 patient tests were run in duplicate with approximately equal numbers of venous, arterial and capillary samples. Pooled pair-wise precision was estimated over three concentration ranges.

Range	<22	22-100	>100
N	253	143	12
Mean reading, mg/dL	13.1	44.2	111.1
Pair precision (SD), mg/dL	0.6	1.2	1.6
$\%CV$	4.6%	2.7%	1.4%

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

Whole Blood Linearity Study (CLSI EP06-A⁴): This study was performed in-house on multiple whole blood samples with BUN values spanning the reportable range. Linearity is reported versus theoretical BUN values based on gravimetric mixtures of high and low BUN samples (as measured using an in-house standard whole blood BUN method). Three card lots were used in this study.

Test Range	Slope	Intercept	R
4-119 mg/dL	1.020	0.40	0.9989

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A3². In the method comparison statistics table, N is the number of patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Method comparison studies were performed at three sites in two hospitals. Venous, arterial and capillary patient samples for a total of over 140 results for each blood type were compared with an IDMS-traceable plasma/serum-based laboratory system.

BUN [mg/dL]	Roche Cobas 8000⁸ *
N	433
Sxx	0.5
Syy	0.9
Slope	0.985
Intercept	0.3
Syx	1.8
Xmin	3
Xmax	118
R	0.997
Mean Bias at 26 mg/dL	-0.1 ± 0.2

* Patient samples approximately equal numbers of venous, arterial and capillary samples versus Roche Cobas 8000⁶.

D. Limitations and Interferences

Interference testing³ was performed in-house on the epoc BUN sensor. In each of these tests, a pooled human serum specimen was aliquoted into two (2) samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The BUN bias between the mean of six (6) replicates on both the control sample and the test sample with added interferent was calculated.

Unacceptable interference bias was defined as producing a significant error more than 5% of the time. The concentration of interfering substance considered as causing no clinically significant interference is defined as a bias (difference between the test and the control sample) of ≤ 1.77 mg/dL for BUN concentrations ≤ 22 mg/dL.

Clinically significant interfering substances are itemized below:

- Samples contaminated with benzalkonium salts used as coatings for in-dwelling lines may cause elevated BUN results. For proper line-flushing procedures refer to CLSI H11-A4⁷;
- Citrate will have no significant effect up to 6.0 mmol/L (176.5 mg/dL) after which it will decrease the BUN concentration by up to 0.26 mg/dL BUN per mmol/L citrate;
- EDTA will have no significant effect up to 4.5 mmol/L (167.5 mg/dL) after which it will decrease the BUN concentration by up to 0.43 mg/dL BUN per mmol/L EDTA;

- Glutathione reduced will have no significant effect up to 1.7 mmol/L (52.2 mg/dL), after which it will increase the BUN concentration by up to 1.91 mg/dL BUN per mmol/L glutathione reduced. Blood glutathione (GSH) in human subjects is ~0.79-1.05 mmol/L⁸. Long term oral glutathione reduced supplementation (250-1,000 mg/day administered for 6 months) increases glutathione plasma levels by ~0.2-8 µmol/L (~0.01-0.25 mg/dL)⁸. Short-term, oral intake of glutathione reduced does not affect plasma glutathione levels⁹;
- β-Hydroxybutyrate will have no significant effect up to 17.2 mmol/L (216.9 mg/dL), after which it will decrease the BUN concentration by up to 0.11 mg/dL BUN per mmol/L hydroxybutyrate. The reference range for β-hydroxybutyrate in plasma is <0.4 to 0.5 mmol/L^{10,11,12}. β-hydroxybutyrate concentration over 3 mmol/L are indicative of ketoacidosis; in very severe diabetic ketoacidosis the concentration may exceed 25 mmol/L¹³;
- Hydroxyurea will have no significant effect up to 1.3 mmol/L (9.9 mg/dL), after which it will increase the BUN concentration by up to 1.61 mg/dL BUN per mmol/L hydroxyurea. The recommended dose of hydroxyurea for patients range from 15 mg/kg/day to 30 mg/kg/day¹⁴. A treatment dose of 2,000 mg/day (~30 mg/kg) results in maximum plasma concentration of ~800 µmol/L with oral administration and ~1 mmol/L with intravenous method¹⁵;
- N-acetyl cysteine will have no significant effect up to 9.2 mmol/L (150.1 mg/dL), after which it will increase the BUN concentration by up to 0.11 mg/dL BUN per mmol/L N- acetyl cysteine. It has been reported that 1 mmol/L N-acetyl cysteine is therapeutically unattainable in plasma¹⁶. The therapeutic level for N-acetyl cysteine is 0.3 mmol/L¹⁷;
- Nithiodote will have no significant effect up to 4.1 mmol/L (64.8 mg/dL) after which it will decrease the BUN concentration by up to 0.41 mg/dL BUN per mmol/L Nithiodote. The expected peak sodium thiosulfate plasma concentration following a 12.5 g of Nithiodote is 16.7 mmol/L¹⁸;

The following levels of exogenous interferences were tested and found to be clinically insignificant: 1.324 mmol/L (20 mg/dL) acetaminophen, 2 mmol/L (21.6 mg/dL) Li acetoacetic acid, 3.62mmol/L (65.2 mg/dL) acetyl salicylic acid, 1 mmol/L (5.349 mg/dL) ammonium chloride, 342 µmol/L (6.8 mg/dL) Na ascorbate, 37.5 mmol/L (386 mg/dL) Na bromide, 2.643 mmol/L (125.9 mg/dL) Na cefazolin, 1.46 mmol/L (96.6 mg/dL) Na ceftriaxone, 5.87 µmol/L (0.1 mg/dL) dopamine HCl, 86.8 mmol/L (400 mg/dL) ethanol, 50 µmol/L (4.46 mg/dL) (Flaxedil™) gallamine triethiodide, 28 mmol/L (0.5 g/dL) glucose, 2.55 mmol/L (156 mg/dL) oxidized glutathione, 5 mmol/L (38 mg/dL) glycolic acid, 20 U/mL heparin, 2.43 mmol/L (50 mg/dL) ibuprofen, (0.5%) 500 mg/dL intralipid, 1.3 mmol/L (19.5 mg/dL) Na iodide, 1 mmol/L (12 mg/dL) L-cysteine, 25 µmol/L (~0.5 mg/dL) L-Dopa, 3.2 mmol/L (13.5 mg/dL) lithium chloride, 6 mmol/L (210.8 mg/dL) Na metamizole, 2 mmol/L (90 mg/dL) methotrexate, 0.22 mmol/L (4 mg/dL) oxalate (K) monohydrate, 248 µmol/L (6.5 mg/dL) Na pentothal, 1 mmol/L (12.2 mg/dL) Na perchlorate, 4.34 mmol/L (69.5 mg/dL) Na salicylate, 1.72 mmol/L (16.7 mg/dL) K thiocyanate, 719 µmol/L (19.2 mg/dL) leflunomide, 1002 µmol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: 342 µmol/L (28.8 mg/dL) bilirubin conjugated, 428 µmol/L (25 mg/dL) bilirubin unconjugated, 35 mmol/L bicarbonate, Hct 20% to 60% PCV, 6.6 mmol/L (74 mg/dL) lactate, pH 6.8 to 8, 3.5% to 10% total protein, 1.4 mmol/L (23.5 mg/dL) uric acid.


E. References

1. B.E. Statland, Clinical Decision Levels for Lab Tests, Medical Economic Books, Oradell, NJ, 1987.
2. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline-Second Edition, CLSI document EP09-A3 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2013.
3. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
4. CLSI. Evaluation of the Linearity of Quantitative Measurement Procedures; Approved Guideline, CLSI document EP06-A (ISBN 1-56238-498-8), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2003.
5. CLSI. Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline-Third Edition, CLSI document EP05-A3 (1-56238-967-X), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2014.
6. Roche Cobas, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
7. CLSI. Procedures for the Collection of Arterial Blood Specimens; Approved Standard, CLSI document H11-A4 (ISBN 1-56238-545-3), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
8. Richie J.P., Nichenametla S., Neidig W., Calcagnotto A., Haley J.S., Schell T.D., Muscat J.E. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione, *Eur J Nutr.*, 54: 251.
9. Allen J. and Bradley R.D. (2011). Effects of Oral Glutathione Supplementation on Systemic Oxidative Stress Biomarkers in Human Volunteers, *J Altern Complement Med.*; 17(9): 827-833.
10. Guerci B, B. M. (2003). Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients. *Diabetes Care.*, 26(4), 1137-1141.
11. Laffel L. (1999). Ketone bodies: A review of physiology, pathophysiology and application of monitoring to diabetes., *Diabetes Metab Res Rev.*, 15(6), 412-426.
12. Chiu RW., Ho CS., Tong SF., Ng KF., Lam CW. (2002) Evaluation of a new handheld biosensor for point-of-care testing of whole blood beta-hydroxybutyrate concentration., *Hong Kong Med J.*, 8(3), 172-176.
13. LaGow B et al., eds. PDR Lab Advisor. A Comprehensive Point-of-Care Guide for Over 600 Lab Tests. First ed. Montvale, NJ: Thomson PDR; 2007.
14. Bristol-Myers Squibb. Hydrea (hydroxyurea capsules, USP) prescribing information. Princeton, NJ; March 2001.
15. Rodriguez, G.I.; Kuhn, J.G.; Weiss, G.R.; Hilsenbeck, S.G.; Eckardt, J.R.; Thurman, A.; Rinaldi, D.A.; Hodges, S.; Von Hoff, D.D.; Rowinsky, E.K. (1998). A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. *Blood*, 91(5), 1533-1541.
16. Whillier S., Raftos J.E., Chapman B., Kuchel P.W. (2009). Role of N-acetylcysteine and cystine in glutathione synthesis in human erythrocytes. *Redox Report: Communications in Free Radical Research*, 14(3), 115.
17. Ventura P., Panini R., Pasini M.C., Scarpetta G., Salvioli G. (1999). N-Acetyl Cysteine Reduces Homocysteine Plasma Levels After Single Intravenous Administration by Increasing Thiols Urinary Excretion. *Pharmacological Research*. 40(4), 345-350.
18. S.M. Wendrot, T.N. Heady, D.M. Haverstick, L.M. Bachmann, M.G. Scott, J.C. Boyd, and D.E. Bruns. Falsely increased chloride and missed anion gap elevation during treatment with sodium thiosulfate. *Clinica Chimica Acta* 2014; 431: 77-79.

12.14 Creatinine (Crea)

Creatinine is measured by amperometry¹. Each creatinine sensor is a three layer enzyme electrode, comprising a first immobilized enzyme creatinine-conversion underlayer coated onto a gold electrode, a second immobilized enzyme creatine-screening layer and a third diffusion barrier layer.

The creatinine electrode underlayer contains the enzymes Creatinine Amidohydrolase, Creatine Amidinohydrolase and Sarcosine Oxidase which convert creatinine to hydrogen peroxide in an enzyme → product cascade,



and then uses the underlying gold electrode to detect the enzymatically produced hydrogen peroxide. Peroxide detection is by redox-mediated horseradish-peroxidase (HRP)-catalyzed reduction.



The reduction current is proportional to the concentration of creatinine in the test fluid.

12.14.1 Indications for Use

The Creatinine test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Creatinine measurements from the epoc Blood Analysis System are used in the diagnosis and treatment of certain renal diseases and in monitoring renal dialysis.

12.14.2 Contents

Each test card incorporating a Creatinine test contains a sensing electrode with redox mediated enzymatic membrane layers covered with an oxygen permeable diffusion layer, a reference electrode, a counter electrode and a calibrator fluid containing a known concentration of creatinine.

12.14.3 Traceability

The epoc Creatinine test is calibrated to an IDMS-traceable whole blood method and reports plasma equivalent concentrations. Creatinine concentration values assigned to controls and calibrator fluids are traceable to NIST standard SRM 967.

12.14.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.14.5 Additional Information

Refer to Section 3 “epoc System Operation” in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 “Quality Assurance” in this manual for quality control requirements.

12.14.6 Measurement Range

	Measurement Range	Reference Range ^{2,9}
Creatinine	0.30 – 15.00 mg/dL	0.51 – 1.19 mg/dL
	27 – 1326 μ mol/L	45 – 105 μ mol/L

12.14.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2³ for method comparison studies, CLSI EP07-A2⁴ for interference studies, CLSI EP06-A2⁷ for linearity studies, and CLSI EP05-A2⁵ for precision studies.

A. Precision Data

Precision (CLSI EP05-A2⁵): Three card lots card lots using at least 25 epoc Readers with replicate measurements were run in-house twice a day for twenty days for each fluid. In the precision data tables below, SD_{WD} denotes within-day standard deviation, SD_{DD} denotes day-to-day standard deviation, SD_T denotes total standard deviation, %CV_{WD} denotes within-day coefficient of variation, and %CV_T denotes total coefficient of variation.

Aqueous Control	Units	N	Mean	SD _{WD}	SD _{DD}	SD _T	%CV _{WD}	%CV _T
High Level	mg/dL	241	5.50	0.197	0.112	0.226	3.6%	4.1%
Low Level	mg/dL	239	0.71	0.030	0.017	0.035	4.2%	4.9%

Pooled Whole Blood Precision Data: One hundred twenty seven patient samples were run in duplicate with approximately equal numbers of venous, arterial and capillary samples. Pooled pair-wise precision was estimated over three concentration ranges.

Range	≤2	2 – 10	>10
N	88	44	22
Average Reading, mg/dL	0.74	5.96	13.40
Pair Precision (SD), mg/dL	0.05	0.28	0.67
%CV	6.4%	4.6%	5.0%

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

Whole Blood Linearity Study (CLSI EP06-A⁷): This study was performed in-house on multiple whole blood samples with *Creatinine* values spanning the reportable range. Linearity is reported versus theoretical creatinine values based on gravimetric mixtures of high and low creatinine samples (as measured using an in-house standard whole blood creatinine method with IDMS traceability). Three card lots were used in this study.

Test Range	Slope	Intercept	R
0.251 – 15.5 mg/dL	1.00	0.07	0.995

C. Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2³. In the method comparison statistics table, N is the number of patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Venous, arterial and capillary patient samples were compared with an IDMS-traceable serum-based laboratory system.

Crea	Roche Cobas 6000 ¹⁰
N	144*
Sxx	0.10
Syy	0.30
Slope	1.03
Intercept	-0.10
Syx	0.45
Xmin	0.30
Xmax	14.80
R	0.995
Mean Bias in Estimated Glomerular Filtration Rate Range of Interest (1.00–1.50 mg/dL)	-0.06

*Patient samples: approximately equal numbers of venous, arterial, and capillary samples

D. Limitations and Interferences

Interference testing⁴ was performed in-house on the epoc creatinine sensor. In each of these tests a pooled human serum specimen was aliquoted into two (2) samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The creatinine bias between the mean of six (6) replicates on both the control sample and the test sample with added interferent was calculated.

Unacceptable interference bias was defined as producing a significant error more than 5% of the time. The concentration of interfering substance considered as causing no clinically significant interference is defined as a bias (difference between the test and the control sample) of ≤ 0.23 mg/dL for creatinine concentrations ≤ 2 mg/dL and $\leq 6.8\%$ for creatinine concentrations > 2 mg/dL.

Clinically significant interfering substances are itemized below:

- Creatine will have no significant effect up to 0.10 mmol/L (1.34 mg/dL) after which it will increase the creatinine concentration by up to 2.17 mg/dL creatinine per mmol/L creatine. The reference range of creatine in plasma is 8 – 31 μ mol/L (0.1–0.4 mg/dL) in males and 15 – 53 μ mol/L (0.2 – 0.7 mg/dL) in females¹¹;
- Iodide will have no significant effect up to 0.45 mmol/L (5.74 mg/dL) after which it will decrease the creatinine concentration by up to 0.49 mg/dL creatinine per mmol/L iodide;
- N-acetyl cysteine will have no significant effect up to 0.47 mmol/L (7.70 mg/dL) after which it will decrease the creatinine concentration by up to 0.72 mg/dL creatinine per mmol/L N-acetyl cysteine. It has been reported that 1 mM N-acetyl cysteine is therapeutically unattainable in plasma⁸. The therapeutic level for N-acetyl cysteine is 0.3 mM¹².

Ethylene glycol plus three metabolism products - Glycolic Acid, Glyoxylic Acid and Oxalic Acid - were tested for interference. Ethylene glycol, glyoxylic acid, and oxalic acid do not interfere significantly with epoc creatinine.

- Glycolic acid will have no significant effect up to 1.69 mM, after which it will decrease the creatinine reading by up to 5% / 1 mM glycolic acid.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 1.324 mmol/L (20 mg/dL) acetaminophen, 3.62 mmol/L (65.2 mg/dL) acetylsalicylic acid, 342 μ mol/L (6.8 mg/dL) Na ascorbate, 3.4 μ mol/L (0.1 mg/dL) EDTA, 71 μ mol/L (1.7 mg/dL) methyldopa, 2.55 mmol/L (156 mg/dL) oxidized glutathione, 2.55 mmol/L (78 mg/dL) reduced glutathione, 920 μ mol/L (6.96 mg/dL) hydroxyurea, 282 μ mol/L (4mg/dL) isoniazid (nydrazid), 0.8% (800 mg/dL) intralipid, 3 μ mol/L (0.1 mg/dL) dobutamine, 5.87 μ mol/L (0.1 mg/dL) dopamine, 86.8 mmol/L (400 mg/dL) ethanol, 105 μ mol/L (0.44 mg/dL) fluoride, 133 μ mol/L (0.4 mg/dL) formaldehyde, 55 mmol/L (990 mg/dL) glucose, 0.4 mmol/L (5 mg/dL) guaiacol, 3000 U/L heparin, 2.43 mmol/L (50 mg/dL) ibuprofen, 0.1 mmol/L (2.0 mg/dL) L-Dopa, 51.2 μ mol/L (1.2 mg/dL) lidocaine, 248 μ mol/L (6 mg/dL) thiopental, 2.37 mmol/L (64 mg/dL) tolbutamide, 2.643 mmol/L (120 mg/dL) cefazolin, 1.46 mmol/L (81 mg/dL) ceftriaxone, 4.34 mmol/L (70 mg/dL) salicylate, 6.88 mmol/L (40 mg/dL) thiocyanate, 10 mmol/L (104 mg/dL) β -hydroxybutyrate, 37.5 mmol/L (300 mg/dL) bromide, 20 mmol/L (384 mg/dL) Na citrate, 78.1 μ mol/L (6.4 mg/dL) rifampicin, 5 μ mol/L (0.7 mg/dL) bacitracin, 30.2 μ mol/L (1 mg/dL) ciprofloxacin, 48.6 μ mol/L (1.8 mg/dL) levofloxacin, 2.4 μ mol/L (0.08 mg/dL) norfloxacin, 719 μ mol/L (19.2 mg/dL) leflunomide, 1002 μ mol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: +342 μ mol/L (+20.1mg/dL) bilirubin unconjugated, +342 μ mol/L (+28.8 mg/dL) bilirubin conjugate, 109 mmHg CO₂, 15 mmHg CO₂, +40 mmol/L (+244 mg/dL) bicarbonate, pH >8.0, pH < 6.8, Hct<10PCV, Hct>75PCV, <6% protein, >9% protein, 1.4 mmol/L (23.5 mg/dL) uric acid. 6.6 mmol/L (74 mg/dL) lactate, 131 mmHg O₂, 22 mmHg O₂, 0.25 mmol/L (2.9 mg/dL) proline, 1 μ mol/L (0.01 mg/dL) sarcosine, 42.9 mmol/L (258 mg/dL) urea.

E. References

1. P. D'Orazio, M.E. Meyerhoff, "Electrochemistry and Chemical Sensors", Chapter 4 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St.Louis, 2006.
2. Reference Ranges Table 56-1 in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
3. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
4. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
5. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
6. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
7. CLSI. Evaluation of the Linearity of Quantitative Measurement Procedures; Approved Guideline, CLSI document EP06-A (ISBN 1-56238-498-8), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2003.
8. S. Whillier, J.E. Raftos, B. Chapman, P.W. Kuchel, "Role of N-acetylcysteine and cysteine in glutathione synthesis in human erythrocytes." Redox Report: Communications In Free Radical Research, 2009, vol. 14, issue 3, p 115.
9. F. Ceriotti, J.C. Boyd, G Klein, J. Henny, J. Queralto, V. Kairisto, M. Panteghini, IFCC Committee on Reference Intervals and Decision Limits (C-RIDL), "Reference Intervals for Serum Creatinine Concentrations: Assessment of Available Data for Global Application", Clin. Chem. 54:3, p559-566, 2008
10. Roche Cobas, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
11. Henry's Clinical Diagnosis and management by Laboratory Methods, Eds. McPherson & Pincus, 22nd Edition, Elsevier Sanders, 2011.
12. P. Ventura, R. Panini, M. C. Pasini, G. Scarpetta, G. Salvioli, "N-Acetyl-Cysteine Reduces Homocysteine Plasma Levels After Single Intravenous Administration by Increasing Thiols Urinary Excretion." Pharmacological Research. Volume 40, Issue 4, October 1999, P. 345-350.

12.15 Hematocrit (Hct)

Hematocrit is measured by AC conductometry using two (2) gold electrodes. The conductance of the blood sample in the fluidic path between the two (2) electrodes, after correction for variable plasma conductivity through the measurement of sodium concentration, is inversely proportional to the hematocrit value.

12.15.1 Indications for Use

The Hct test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as a semi-automatic in vitro diagnostic device for the quantitative testing of human samples of heparinized or un-anticoagulated arterial, venous, or capillary whole blood in the laboratory or at the point of care.

Measurement of Hct distinguishes normal from abnormal states of blood volume, such as anemia and erythrocytosis.

12.15.2 Contents

Each Test Card incorporating an Hct test contains two (2) gold sensing electrodes and a calibrator fluid containing a known concentration of dissolved electrolytes with a known conductivity.

12.15.3 Traceability

Hematocrit values assigned to controls and calibrator fluids are traceable to the standard method for measuring packed cell volume by the microhematocrit method, using whole blood with K₃EDTA anticoagulant, – applicable standard CLSI H07-A3¹.

12.15.4 Sample Collection

Refer to 12.2.6 Sample Collection.

12.15.5 Additional Information

Refer to Section 3 “epoc System Operation” in this manual for detailed sample collection and system operating instructions for conducting a blood test.

Refer to Section 9 “Quality Assurance” in this manual for quality control requirements.

12.15.6 Measurement Range

	Measurement Range	Reference Range²
Hct	10 – 75%	38 – 51%
	0.10 – 0.75	0.38 – 0.51 L/L

12.15.7 Performance Data

Typical performance data summarized below were obtained in-house as well as in healthcare facilities by healthcare professionals trained in the use of the epoc System. Experimental designs conformed to applicable CLSI guidelines.

Applicable standards include: CLSI EP09-A2³ for method comparison studies, CLSI EP07-A2⁴ for interference studies and CLSI EP05-A2⁷ for precision studies.

A. Precision Data

In the precision data tables below, SD_{WR} denotes within run standard deviation and SD_T denotes total standard deviation.

In-house Precision 1: commercial hematocrit controls run in a 20 day precision study⁹ with 2 measurements each day per each control level. 4 manufactured lots, 6 different epoc Readers

Aqueous Control	Units	Mean	SD _{WR}	%CV	SD _T	%CV
Level 1	%PCV	25.3	0.4	1.5	0.4	1.6
Level 3	%PCV	46.1	0.7	1.5	0.7	1.5

In-house Precision 2: whole blood samples run on 20 sequential manufactured lots using at least 8 different epoc Readers, with 12 replicates per each blood sample per lot.

Whole Blood Samples	Units	Mean	Mean SD _{WR}	%CV
Blood level 1	%PCV	44.0	0.7	1.6
Blood level 2	%PCV	22.0	0.7	3.0

Clinical Site Precision: 10 replicates of whole blood Patient samples run by different operators of the epoc system at different point-of-care sites. Each precision study employed 5 different epoc Readers.

		Units	Mean	SD _{WR}	%CV
Site 1	Operator 1	%PCV	40	0.6	1.4
	Operator 2	%PCV	40	0.5	1.3
Site 2	Operator 3	%PCV	39	0.6	1.6
	Operator 4	%PCV	41	0.5	1.2
	Operator 5	%PCV	40	0.6	1.4
Site 3	Operator 6	%PCV	40	0.8	2.0
	Operator 7	%PCV	38	0.7	1.9

Because the SDs presented here are examples of typical performance, it is expected that, occasionally, SDs from an individual precision study may be higher or lower than these values. Each site must establish whether the results of their precision studies are clinically acceptable. Alternatively, an f test can be used to determine whether their precision is statistically equivalent to typical precision values summarized above.

B. Linearity Data

This study was performed in-house on multiple whole blood samples with hematocrit level spanning the reportable range. Linearity is reported versus an in-house standard spun hematocrit method.

	Test Range	Units	Slope	Intercept	R
Hct	7.5 – 81.2	% PCV	1.036	-0.155	0.998

C. Clinical Sites Method Comparison Data

Linear regression analysis was performed on the method comparison data in accordance with CLSI EP09-A2³. In the method comparison statistics table, N is the number of Patient specimens in the data set, Sxx and Syy are the pooled pair-wise imprecision of the comparative and epoc test methods respectively, Syx is the standard error and R is the correlation coefficient.

Clinical Site Method Comparison 1: In one hospital study the epoc System was compared with the i-STAT 300⁵ in the lab (two test occasions), and then at three (3) point-of-care sites.

Method Comparison Summary Statistics: whole blood

X: i-STAT 300 test

Y: epoc test

Hct	Lab 1	Lab 2	POC 1	POC 2	POC 3	All
N	34	23	35	28	22	142
Sxx	0.49	0.66	0.46	0.67	0.69	0.58
Syy	0.69	0.42	0.65	0.57	0.80	0.64
Intercept	-1.5	1.3	0.0	-0.4	-0.4	-1.1
Slope	1.086	1.006	1.034	1.027	1.051	1.066
Syx	1.28	1.17	1.05	1.48	1.82	1.36
Xmin	19	24	28	23	24	19
Xmax	73	57	41	39	60	73
R	0.995	0.990	0.964	0.955	0.976	0.987
Mean Bias (%CV)						1.7

Clinical Site Method Comparison 2: In another hospital study, the epoc System was compared with the Radiometer ABL 735⁶ in the lab. (The ABL 735 hematocrit value was calculated from the measured hemoglobin.)

Method Comparison Summary Statistics: whole blood

X: Radiometer ABL 735

Y: epoc test

Hct	N	Sxx	Syy	Intercept	Slope	Syx	Xmin	Xmax	R	Mean Bias (%CV)
Lab	77	1.42	1.16	-2.3	1.006	2.84	21	63	0.964	-1.6

D. Limitations and Interferences

Blood samples must be well mixed in order to obtain accurate hematocrit results. The best way to ensure this is to test the sample immediately after collection. For samples where testing delays of greater than one minute occur, cells should be thoroughly re-mixed by rolling the sample between the hands for several rotations in both directions.


Note: Thin diameter collection devices (for example, 1cc syringes or epoc Care-Fill Capillary Tubes) may be difficult to re-mix. Therefore, it is recommended that testing from these devices not be delayed. Refer to 12.2.6 Sample Collection.

Interference testing⁴ was performed in-house on the epoc hematocrit sensor. In each of these tests a whole blood specimen was aliquoted into two samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The hematocrit bias between the mean of six replicates on both the control sample and the test sample with added interferent was calculated.

Note: Automated hematology analyzers may underestimate or overestimate hematocrit values due to the differing osmotic effects on RBC in the isotonic buffer matrix, compared to their native plasma matrix⁸.

Clinically significant interfering substances are itemized below:

- Total protein content will affect the hematocrit results as follows: an increase (decrease) of 1 g/dL of total protein will increase (decrease) the hematocrit value by approximately 1% PCV. Total protein levels vary with the clinical populations². Low total protein values may be found in neonates, burned Patients, Patients receiving large volumes of IV fluids, and Patients undergoing cardiopulmonary bypass (CPB) and extra-corporeal membrane oxygenation (ECMO). For the case of hemodilution, the user should activate the hemodilution correction factor or "HCF" in the epoc Host (see Section 6 "epoc Host" and Section 7 "epoc Host Administration" in this manual for details). The HCF corrects hematocrit for low protein in blood samples known to be diluted with fluids that do not contain protein. There is no HCF applied for Hct over 42%. It is recommended that each practice verify the use of the HCF algorithm as well as the time interval that the HCF should be selected during the recovery period;



- A significant increase in white blood cell count may increase the hematocrit result;
- Abnormally high lipids may increase hematocrit results.

The following levels of exogenous interferences were tested and found to be clinically insignificant: 447 mg/dL ethanol, 1 mmol/L sodium pentothal, 4.3 mmol/L acetyl salicylate, 0.4 mmol/L ascorbate, 4.3 mmol/L salicylate, 1 mmol/L iodide, 2.2 mmol/L ibuprofen, 4 mmol/L lithium, 19 mmol/L bromide, 2.64 mmol/L propofol, 0.7 mmol/L cefotaxime, 0.16 mmol/L ampicillin, 1 mmol/L sodium perchlorate, 4.8 µM Zofran™, 2.5 mM N-acetylcysteine, 0.7 mM metronidazole, 719 µmol/L (19.2 mg/dL) leflunomide, 1002 µmol/L (26.9 mg/dL) teriflunomide.

The following levels of endogenous interferences were tested and found to be clinically insignificant: 0.8g/dL lipids, 9.1 mmol/L cholesterol, 20 mmol/L β -hydroxybutyrate, 2mmol/L (24mg/dL) L-cysteine, 0.26 mmol/L bilirubin, +2 mmol/L phosphate.

E. References

1. CLSI. Procedure for determining Packed Cell Volume by the Microhematocrit method; Approved Standard, third edition, CLSI document H07-A3 (ISBN 1-56238-413-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2000.
2. B.E. Statland, Clinical Decision Levels for Lab Tests, Medical Economic Books, Oradell, NJ, 1987.
3. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline, second edition, CLSI document EP09-A2 (ISBN 1-56238-472-4), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
4. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline, CLSI document EP07-A2 (ISBN 1-56238-480-5), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
5. i-STAT 300, Abbott Point of Care Inc., 104 Windsor Center Drive, East Windsor, NJ 08520, "i-STAT" is a registered trademark of Abbott Laboratories.
6. Radiometer ABL 735, Radiometer Medical ApS, Åkandavej 21, DK-2700 Brønshøj, Denmark, "Radiometer" and "ABL" are registered trademarks of Radiometer Medical ApS.
7. CLSI. Evaluation of Precision in Clinical Chemistry Devices; Approved Guideline, second edition, CLSI document EP05-A2 (ISBN 1-56238-542-9), CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
8. Osmotic Error in Erythrocyte Volume Determinations, W Beautyman and T Bills, University of Massachusetts Medical School, Berkshire Medical Center, American Journal of Hematology 12:383-389 (1982).

12.16 Calculated Values

Note: Except where noted, calculated values are only available when the measured parameters from which they are derived are displayed.

12.16.1 Calculated Bicarbonate (cHCO₃⁻), Calculated Total Carbon Dioxide (cTCO₂), Base Excess (BE)¹

Note: Alternate analyte acronyms for **cHCO₃⁻** are **HCO₃-act** or **HCO₃-**.

Calculated bicarbonate: $\text{LOG cHCO}_3^- = \text{pH} + \text{LOG pCO}_2 - 7.608$

Calculated TCO₂†: $\text{cTCO}_2 = \text{cHCO}_3^- + 0.0307 \times \text{pCO}_2$

Base Excess (extra cellular fluid): $\text{BE(ecf)} = \text{cHCO}_3^- - 24.8 + 16.2 \times (\text{pH} - 7.4)$

Base Excess (blood): $\text{BE(b)} = (1 - 0.014 \times \text{cHgb}) \times (\text{cHCO}_3^- - 24.8 + (1.43 \times \text{cHgb} + 7.7) \times (\text{pH} - 7.4)) *$

Applicable standards: CLSI C46-A2¹. In above equations, units are mmHg for pCO₂ and g/dL for cHgb.

† Calculated TCO₂ is only available when measured TCO₂ is not reported.

* cHgb is obtained from measured Hematocrit value, even if Hematocrit and cHgb are not displayed.

Measurement Range

	Units of Measure	Measurement Range	Reference Range ⁸⁻¹⁰	
			Arterial	Venous
cHCO₃⁻	mmol/L	1 – 85	21 – 28	22 – 29
	mEq/L			
cTCO₂	mmol/L	5 – 50	22 – 29	23 – 30
	mEq/L			
BE(ecf)	mmol/L	-30 – +30	-2 – +3	-2 – +3
	mEq/L			
BE(b)	mmol/L	-30 – +30	-2 – +3	-2 – +3
	mEq/L			

12.16.2 Calculated Oxygen Saturation (cSO₂)²

Note: Alternate analyte acronym for **cSO₂** is **O2SAT**.

$\text{cSO}_2 = 100(X^3 + 150X) / (X^3 + 150X + 23400)$

$X = \text{pO}_2 \times 10^{(0.48(\text{pH}-7.4)-0.0013(\text{cHCO}_3-25))}$

Measurement Range

	Measurement Range	Reference Range, Arterial
cSO₂	0 – 100%	94 – 98%

Because oxygen saturation also depends on the effects of 2,3 diphosphoglycerate and dysfunctional hemoglobins (carboxy-, met-, and sulfhemoglobin) in blood, the above equation does not account for variations in these values, the oxygen saturation that is reported should only be used as an estimate of the actual value^{1,3,11}. Shifts in the oxyhemoglobin dissociation curve have also been recorded in cases of uremic and diabetic coma, as well as pernicious anemia¹¹. Clinically significant errors can result from

incorporation of such an estimated value for oxygen saturation in further calculations, such as shunt fraction, or by assuming the value obtained is equivalent with fractional oxyhemoglobin.

Oxygen saturation is a useful predictor of the amount of oxygen that is available for tissue perfusion. Some causes for decreased values of cSO_2 include low pO_2 or impaired ability of hemoglobin to carry oxygen.

12.16.3 Anion Gap (AGap)⁸

When measured TCO_2 is reported:

$$\text{Anion Gap: AGap} = (\text{Na}^+) - (\text{Cl}^- + \text{TCO}_2 - 1)$$

$$\text{Anion Gap, K: AGapK} = (\text{Na}^+ + \text{K}^+) - (\text{Cl}^- + \text{TCO}_2 - 1)$$

Otherwise:

$$\text{Anion Gap: AGap} = (\text{Na}^+) - (\text{Cl}^- + c\text{HCO}_3^-)$$

$$\text{Anion Gap, K: AGapK} = (\text{Na}^+ + \text{K}^+) - (\text{Cl}^- + c\text{HCO}_3^-)$$

Applicable reference: Tietz 2nd ed.⁸

Measurement Range

	Units of Measure	Measurement Range	Reference Range
AGap	mmol/L	-14-+95	7-16
	mEq/L		
AGapK	mmol/L	-10-+99	10-20
	mEq/L		

12.16.4 Estimated Glomerular Filtration Rate (GFR)

When Crea measurement is available on the Test Card and enabled by the system administrator for testing, the following estimated Glomerular Filtration Rate (GFR) values may be calculated: **GFRmdr**, **GFRmdr-a**, **GFRckd**, **GFRckd-a**, **GFRckd21**, **GFRswz**.

These values are estimated using different methods and can all be reported on the epoc System.

Note: In earlier epoc System software versions, the only values for estimated Glomerular Filtration Rate were MDRD type. They were shown in test results as simply "eGFR" and "eGFR-a." With more estimated Glomerular Filtration Rate options available, new notations have been introduced: GFRmdr, GFRmdr-a, GFRckd, GFRckd-a, GFRckd21, GFRswz.

Estimated Glomerular Filtration Rate (IDMS-traceable MDRD type):

$$\text{GFRmdr}^{4,5} = 175 \times (\text{Crea}^{-1.154}) \times (\text{Age}^{-0.203}) \times (0.742 \text{ if female, } 1 \text{ if male})$$

Note: Formerly, GFRmdr was named eGFR.

Estimated Glomerular Filtration Rate (IDMS-traceable MDRD type), if African American:

$$\text{GFRmdr-a}^{4,5} = 175 \times (\text{Crea}^{-1.154}) \times (\text{Age}^{-0.203}) \times (0.742 \text{ if female, } 1 \text{ if male}) \times 1.212$$

Note: Formerly, GFRmdr-a was named eGFR-a.

Estimated Glomerular Filtration Rate (CKD-EPI equation):

$GFR_{ckd}^{12-17} = 141 \times \min(Crea/\kappa, 1)^{\alpha} \times \max(Crea/\kappa, 1)^{-1.209} \times 0.993^{Age} \times (1.018 \text{ if female, } 1 \text{ if male})$

Estimated Glomerular Filtration Rate (CKD-EPI equation), *if African American*:

$GFR_{ckd-a}^{12-17} = 141 \times \min(Crea/\kappa, 1)^{\alpha} \times \max(Crea/\kappa, 1)^{-1.209} \times 0.993^{Age} \times (1.018 \text{ if female, } 1 \text{ if male}) \times 1.159$

$\kappa = 0.7$ (females) or 0.9 (males)

$\alpha = -0.329$ (females) or -0.411 (males)

min = indicates the minimum of Crea/ κ or 1

max = indicates the maximum of Crea/ κ or 1

Estimated Glomerular Filtration Rate (CKD-EPI Creatinine Equation (2021)):

$GFR_{ckd21} = 142 \times \min(S_{cr}/K, 1)^{\alpha} \times \max(S_{cr}/K, 1)^{-1.200} \times 0.9938^{Age} \times 1.012$ [if female]

S_{cr} = standardized serum creatinine in mg/dL

$K = 0.7$ (females) or 0.9 (males)

$\alpha = -0.241$ (females) or -0.302 (males)

$\min(S_{cr}/K, 1)$ = the minimum of S_{cr}/K or 1.0

$\max(S_{cr}/K, 1)$ = the maximum of S_{cr}/K or 1.0

Age (years)

Estimated Glomerular Filtration Rate (Bedside Schwartz equation), *for use in children 1-18 years old*:

$GFR_{swz}^{18-20} = 0.413 \times (\text{height}/Crea)$

Crea concentration is in units of mg/dL.

Age (years) and gender (male or female) are user inputs.

Height is expressed in centimeters, also a user input.

Age Range

	Age Range	Note
GFR_{mdr}, GFR_{mdr-a}	18 - 120	GFR _{mdr} , GFR _{mdr-a} values are not reported if Age is less than 18 years old or greater than 120 years old.
GFR_{ckd}, GFR_{ckd-a}, GFR_{ckd21}	19 - 120	GFR _{ckd} , GFR _{ckd-a} values are not reported if Age is less than 19 years old or greater than 120 years old.
GFR_{swz}	1 - 18	GFR _{swz} values are not reported if Age is less than 1 year old or greater than 18 years old.

Measurement Range

	Measurement Range	Reference Range
GFRmdr, GFRmdr-a	2 – 60 or >60 mL/min/1.73m ² *	†
GFRckd, GFRckd-a, GFRckd21	1 – 225 mL/min/1.73m ²	†
GFRswz	1 – 275 mL/min/1.73m ²	†

* Numeric values will be reported for values between 2-60 mL/min/1.73 m². Values >60 will be reported as > 60 mL/min/1.73 m². This range is based on the specific National Kidney Disease Education Program (NKDEP) recommendation for reporting GFRmdr values⁴. GFRmdr > 60 does not exclude the possibility of mild renal disease. Further laboratory testing may be necessary to distinguish normal renal function from mild renal disease.

† Widely accepted reference ranges are not well established for Estimated Glomerular Filtration Rate. Institutions should establish and set their own reference range values.

12.16.5 BUN/Crea Ratio, Urea/Crea Ratio

BUN/Crea ratio and **Urea/Crea** ratio are calculated from two corresponding measured values.

BUN/Crea (mg/mg) = BUN (mg/dL) / Crea (mg/dL)

Urea/Crea (mmol/mmol) = Urea (mmol/L) / Crea (mmol/L)*

Urea/Crea (mg/mg) = Urea (mg/dL) / Crea (mg/dL)

* epoc Host software automatically recalculates Crea results reported in μmol/L to mmol/L.

	Units of Measure	Measurement Range	Reference Range
BUN/Crea	mg/mg	0.2 – 400.0	12.0 – 20.0
Urea/Crea	mmol/mmol	0.8 – 1615.4	48.5 – 80.8
	mg/mg	0.4 – 856.8	25.7 – 42.8

12.16.6 Calculated Hemoglobin (cHgb)^{6,7}

Hemoglobin concentration is calculated from the measured hematocrit according to the relation:

$$\text{cHgb (g/dL)} = \text{Hct (decimal fraction)} \times 34$$

The relation above assumes a normal Mean Corpuscular Hemoglobin Concentration, MCHC of 34%^{6,7}.

Measurement Range

	Measurement Range	Reference Range
cHgb	3.3 – 25 g/dL	12 – 17 g/dL
	2.0 – 15.5 mmol/L	7.4 – 10.6 mmol/L
	33 – 250 g/L	120 – 170 g/L

12.16.7 Alveolar Oxygen (A), Arterial Alveolar Oxygen Tension Gradient (A-a), Arterial Alveolar Oxygen Tension Ratio (a/A)

Note: Alternate acronym for **A** is **pO₂(A)**.

Note: Alternate acronyms for **A-a** are **pO₂(A-a)** and **AaDO₂**. Also referred to as Arterial Alveolar Oxygen Tension Difference.

Note: Alternate acronym for **a/A** is **pO₂(a/A)**.

Entering a patient temperature is required for corresponding temperature-corrected parameters: A(T), A-a(T), a/A(T).

Note: These calculations require the sample type selection of Arterial or Capillary. If these sample types are not selected, these parameters will not be displayed.

Note: If FiO₂ is not entered, these parameters will not be displayed.

These six parameters are calculated as follows.

$$A = \text{FiO}_2 \times (p_{\text{Amb}} - p_{\text{H}_2\text{O}}) - p_{\text{CO}_2} \times (1/\text{RQ} - \text{FiO}_2(1/\text{RQ} - 1))$$

$$A(T) = \text{FiO}_2 \times (p_{\text{Amb}} - p_{\text{H}_2\text{O}}(T)) - p_{\text{CO}_2}(T) \times (1/\text{RQ} - \text{FiO}_2(1/\text{RQ} - 1))$$

$$A-a = A - p_{\text{O}_2}$$

$$A-a(T) = A(T) - p_{\text{O}_2}(T)$$

$$a/A = p_{\text{O}_2} / A$$

$$a/A(T) = p_{\text{O}_2}(T) / A(T)$$

where:

RQ = Respiratory Quotient, input parameter (range 0.01-2.00). If RQ is not entered, 0.86 is used.

FiO₂ = Fraction of inspired O₂, input parameter (range 21-100, %). If FiO₂ is not entered, these parameters will not be displayed.

$$p_{\text{H}_2\text{O}} = 6.275 \text{ kPa}$$

$$p_{\text{H}_2\text{O}}(T) = 6.275 \times 10^{((T-37)(0.0236-0.000096(T-37)))} \text{ kPa, temperature units are } ^\circ\text{C}.$$

pAmb = ambient barometric pressure (measured by epoc Reader) kPa

T = Patient Temperature, input parameter.

Measurement Range

	Measurement Range	Reference Range
A, A(T)	5-800 mmHg	†
	0.67-106.64 kPa	†
A-a, A-a(T)	1-800 mmHg	†
	0.13-106.64 kPa	†
a/A, a/A(T)	0-100 %	†
	0-1	†

† Widely accepted reference ranges are not well established. Institutions should establish and set their own reference range values.

12.16.8 References

1. CLSI. Blood Gas and pH Analysis and Related Measurements; Approved Guideline, CLSI C46-A2, Vol. 29, No. 8, Blood gas and pH analysis and related measurements-Approved Guideline, second edition, Wayne, Pennsylvania, USA, 2009.
2. J.W. Severinghaus, Simple and accurate equations for human blood O₂ dissociation computations, *J. Appl. Physiol.*, 46, 1979, p. 599-602.
3. M.G. Scott, V.A. LeGrys and J.S. Klutts, Chapter 27 of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth edition, C.A. Burtis, E.R. Ashwood, and D.E. Bruns eds., Elsevier Saunders, St. Louis, 2006.
4. National Kidney Disease Education Program Website
http://www.nkdep.nih.gov/labprofessionals/equations_and_GFR.htm
Refer to: Laboratory Professionals > Estimating and Reporting GFR > Equations and GFR Calculators>IDMS-traceable MDRD Study Equation
Also, refer to: <http://nkdep.nih.gov/lab-evaluation/gfr/reporting.shtml>.
5. Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program, *Clinical Chemistry* 2006;52(1):5-18.
6. M.L. Turgeon, *Clinical Hematology-Theory and Procedures*, Little, Brown and Co., Boston/Toronto, 1985.
7. J.D. Bower, P.G. Ackerman and G. Toto, Eds., *Clinical Laboratory Methods*, Chapter 5: Evaluation of formed elements in blood, St. Louis, The C.V. Mosby Company, 1974.
8. Reference Ranges Table 41-20 in Tietz Textbook of Clinical Chemistry – 2nd Edition, C.A. Burtis and E.R. Ashwood eds., Elsevier Saunders, Philadelphia, 1994.
9. B.E. Statland, *Clinical Decision Levels for Lab Tests*, Medical Economic Books, Oradell, NJ, 1987.
10. Pruden E.L., Siggaard-Andersen O., and Tietz N.W., Chapter 30 (Blood Gases and pH), of Tietz Textbook of Clinical Chemistry, Second Edition, ed. C.A. Burtis and E.R. Ashwood. W.B. Saunders Company, Philadelphia, 1994.
11. P.B. Astrup, J.W. Severinghaus, The history of blood gases, acids and bases, 1986, 128-153.
12. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150(9):604-612.
13. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. *Am J Kidney Dis.* 2010;55(4):622-627.
14. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Kidney Dis.* 2010;55(4):648-659.
15. White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. *Am J Kidney Dis.* 2010;55(4):660-670.
16. Becker BN, Vassalotti JA. A software upgrade: CKD testing in 2010. *Am J Kidney Dis.* 2009;55(1):8-10.
17. Inker, AS. Frequently Asked Questions About GFR Estimates. New York: The National Kidney Foundation; 2011.
18. Schwartz GJ and Work DF. Measurement and estimation of GFR in children and adolescents. *J Am Soc Nephrol.* 2009; Nov; 4(11): 1832-643.

19. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol.* 2009; 20: 629-637.
20. Staples A, LeBlond R, Watkins S, Wong C, Brandt J. Validation of the revised Schwartz estimating equation in a predominantly non-CKD population. *Pediatr Nephrol.* 2010 Nov;25(11):2321-6.